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A MATHEMATICAL MODEL OF THE COMBINED β1- AND β2-ADRENERGIC
SIGNALING SYSTEM IN THE MOUSE VENTRICULAR MYOCYTE
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ABSTRACT
The β1- and β2-adrenergic signaling systems play different roles in the functioning of cardiac
cells. Experimental data shows that the activation of the β1-adrenergic signaling system produces
significant inotropic, lusitropic, and chronotropic effects in the heart, while the effects of the β 2adrenergic signaling system is less apparent. In this dissertation, a comprehensive experimentallybased mathematical model of the combined β1- and β2-adrenergic signaling systems in mouse
ventricular myocytes is developed to simulate the experimental findings and make testable
predictions of the behavior of the cardiac cells under different physiological conditions.
Simulations describe the dynamics of major signaling molecules in different subcellular

compartments; kinetics and magnitudes of phosphorylation of ion channels, transporters, and Ca2+
handling proteins; modifications of action potential shape and duration; and [Ca2+]i and [Na+]i
dynamics upon stimulation of β1- and β2-adrenergic receptors (β1- and β2-ARs). The model reveals
physiological conditions when β2-ARs do not produce significant physiological effects and when
their effects can be measured experimentally. Simulations demonstrated that stimulation of β2ARs with isoproterenol caused a marked increase in the magnitude of the L-type Ca2+ current,
[Ca2+]i transient, and phosphorylation of phospholamban only upon additional application of
pertussis toxin (PTX) or inhibition of phosphodiesterases of type 3 and 4. The model also made
testable predictions of the changes in magnitudes of [Ca2+]i and [Na+]i fluxes, the rate of decay of
[Na+]i concentration upon both combined and separate stimulation of β1- and β2-ARs, and the
contribution of phosphorylation of PKA targets to the changes in the action potential and [Ca2+]i
transient. A comprehensive mathematical model of the mouse ventricular myocyte overexpressing
β2-adrenergic receptors was also developed. It was found that most of the β2-adrenergic receptors
are active in control conditions in TG mice. Simulations describe the increased basal adenylyl
cyclase activity; modifications of action potential; the effects on the L-type Ca2+ current and [Ca2+]i
transients upon stimulation of β2-adrenergic receptors in control, after the application of PTX,
upon stimulation with zinterol, and upon stimulation with zinterol in the presence of PTX. The
model also describes the effects of inverse agonist ICI-118,551 on adenylyl cyclase activity, action
potential, and [Ca2+]i transients.
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INTRODUCTION

Mathematical models are used with a great degree of reliance in many disciplines
including engineering, physics, and economics. These models are used to design, study, and
predict outcomes as it relates to those fields of study. Recently these mathematical models
have become more integrated into the biological sciences. Biologically plausible
mathematical models that advance our knowledge of the underlying processes will become
increasingly valuable tools in the understanding of diseases and for drug development.
Particularly, as it pertains here, are the models of cardiac cells that ultimately aid in the
study of arrhythmias and other heart diseases including heart failure.
Since the mid 1900’s, cardiac models have progressed from simple models that replicate
the action potential to models which are detailed and describe the many interacting
components that contribute to the action potential and ionic dynamics. These advances
have been commiserated with the advances in technology which have paved the way for the
discovery of various ionic currents, pumps, transporters, exchangers, proteins and signaling
pathways that all play a part in the complex dynamics of the cardiac myocyte. The
development of cardiac cell models has been an educational exchange between experiment
and modelling where experiments have guided model development and models have made
testable predictions for experiments.
In this chapter, we briefly describe the cardiac conduction system, major mathematical
models that have made fundamental contributions to the progress in the field of cardiac
modeling, and give an outline of the purpose of the study in this dissertation.
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1.1

The Cardiac Conduction System
The cardiac conduction system is the system that controls the heartbeat. The electrical

activity in the conduction system is in the form of the action potentials that propagate through the
system. This pathway begins with the sinoatrial (SA) node where rhythmic activity is generated
and spreads through the atria causing it to contract and send blood to the ventricles. The electric
signal then reaches the atrioventricular (AV) node where it is briefly delayed before passing to
the HIS bundle. The impulse subsequently passes through the left and right bundle branches and
on to the Purkinje fibers where the electrical signal spreads through the ventricles thereby
promoting ventricular contraction and sending blood through the lungs and the body.
While there are mathematical models that describes the whole heart behavior, they
mostly rely on the relatively simple descriptions of the tissue and cellular processes1,2. Usually,
they do not include the change in the heart geometry during contraction. Even at present there is
no well-developed mathematical model that satisfactory describes physiological processes in the
heart, which is built of the different cell types (sino-atrial nodal cells, atrial cells, ventricular
cells, Purkinje cells, etc.). As the cardiac tissue properties are significantly dependent on the
behavior of the cardiac cells (electrical activity, ionic dynamics, contraction), major attention is
paid to the development of comprehensive mathematical models of isolated cardiac cells.

Figure 1.1 The Cardiac Conduction System
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1.2

Cellular Cardiac Mathematical Models
Most cellular mathematical models have been developed for Purkinje fibers, ventricular

cells, and atrial cells. Whereas some early models have been general models, there are many
species specific models including those for the guinea pig, canine, rat, mouse, and human.
Model development has increased in its scope over the past decades. Beginning with models that
sought to describe the electrical activity with respect to the major ionic currents to models that
include comprehensive descriptions of the Ca2+, Na+, and K+ dynamics. Recent models have
included protein signaling networks and the effects of signaling pathways on cellular functions.
Whereas there have been numerous models developed for different purposes, we will limit the
discussion here to a brief synopsis of a few models which have led to the model described in this
dissertation.
The earliest cardiac model was Noble’s3 model of the Purkinje fiber cell which was based
on the work of Hodgkin and Huxley’s description of the properties of the squid axon nerve4.
Noble’s alterations of the Hodgkin & Huxley equations to replicate the action and pace-maker
potentials of cardiac Purkinje fiber cells involved several alterations and observations. To
coincide with experimental work at the time, Noble adopted the convention that positive currents
are outwards such that the potential described is the inside potential with regard to the outside
potential. Taking into account that decreases in membrane conductance coincide with
depolarization5, the Noble model implements the potassium current as passing through different
channels with different conductance (gk1 and gk2). Upon membrane depolarization, gk1 falls and
is an instantaneous function of the membrane potential resulting in an inward current, whereas
gk2 rises slowly upon depolarization and yields an outward current. The sodium conductance
(gna) is modeled closely to that of Hodgkin and Huxley where gna, upon depolarization, has an
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initial large increase that is a function of the prior membrane potential and subsequently falls,
even with sustained depolarization. Capturing this activity required the use of two opposing
membrane potential dependent variables whose time constants were independent of each other.
The Noble Model also included a leak current, with conductance gAn, which was attributed to
chloride ions. The four variable model is depicted schematically in Figure 1.2.

Figure 1.2 The Noble Model. A schematic representation of the Noble Model. The model includes two
inward currents, representing K+ and Na+ currents along with an outward leak current.

The computations from Noble’s equations yielded traces very close to that of the changes
in the membrane potential of Purkinje fibers. A clear action potential with a distinctive spike
that is trailed by a plateau with an interval of about 300ms which yields to a rapid repolarization
and concludes with a slow depolarization until the next action potential is initiated. The
acknowledged discrepancy with Noble’s computations is that experimental action potentials had
a much higher maximum rate of depolarization than the 100mV/sec obtained by Noble. Noble’s
work also included a description of the contributions of the various conductances to the action
potential. It was noted that at the initiation of an action potential, gk (the sum of the conductance
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of gk1 and gk2) decreases corresponding to the decrease in gk1. The total conductance, gk, then
slowly rises due to the increase in gk2 during the plateau phase. Since gk1 increases upon
repolarization, gk continues to rise until depolarization where it begins to slowly fall. The spike
in the action potential coincides with a large initial increase in gna attributable to the fast rise in
the membrane potential dependent m variable. The subsequent fall is due to the opposing fall of
the membrane potential dependent h variable. Following an undershoot, gna reaches a plateau as
the contrasting m and h variables keep the conductance relatively constant throughout the plateau
of the action potential. Repolarization of the action potential coincides with a fall in gna where it
again remains relatively constant until the initiation of the next action potential. In addition to
the change in conductances, Noble also computed the ionic currents and fluxes associated with
the action potential. The model was also able to corroborate several experimental observations
including all or nothing repolarization, impendence change, changes in ionic permeability, and
decreased length of the action potential with an increased stimulation frequency6.
The first ventricular cell model was presented by Beeler and Reuter7 and was based
primarily on voltage clamp experiments. The Beeler-Reuter model focused on the role of the
inward current (Is) carried by Ca2+ ions and its contributions to the action potential plateau. The
model, as depicted in Figure 1.3, utilized 8 variables with 4 currents: an excitatory inward
sodium current, Ina, a slow inward current, Is, an outward potassium current, Ik1, and an inward
rectifying current, Ix1, Where Ina, Is, and Ix1 are voltage- and time-dependent and Ik1 being time
independent.
The currents in the Beeler and Reuter model follow the Hodgkin and Huxley form for equations
of ionic currents. Construction of the time activated and time independent currents, Ix1 and Ik1
respectively, were implemented from that of McAllister et al8. The inward sodium current, Ina,
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has its basis in the Hodgkin and Huxley equations with a modification taken from Haas et al9. in
that a second inactivation parameter is implemented with the same membrane potential
dependence and differing time constants. The Beeler-Reuter model successfully replicates the
components of the standard action potential of the ventricular myocyte where the initial spike is
followed by a characteristic “notch” which yields to the plateau of the action potential and then
repolarization.

Figure 1.3 The Beeler-Reuter Model. A schematic representation of the eight variable and four current
Beeler-Reuter model7.

Beeler and Reuter observed that during the notch there is a slight delay between the fall
of the inactivation parameter for Is, f, and the rise of the activation parameter for Ix1, x1. The
plateau, in this sense is maintained by the slightly steeper decline in the f parameter compared to
the rise in x1. The Beeler –Reuter model was able to emulate several of the experimental
observations such as all or nothing repolarization, the slow Na+ recovery from inactivation as
well as the dependence of action potential duration on frequency of stimulation.
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Motivated by an increase in experimental data, particularly with regard to the sodium
current, and a need to incorporate intracellular and extracellular ion concentration changes,
DiFrancesco and Nobel published a new model of the Purkinje Fibers10.

The sixteen variable

DiFrancesco –Noble model (Fig 1.4) was the first to incorporate mechanisms by which ionic
movement down the electrochemical gradient can be reversed in the form of the sodiumpotassium pump and sodium-calcium exchanger.

Figure 1.4 The DiFrancesco-Noble Model. A schematic representation of the DiFrancesco-Noble
Model10 which included the sodium-potassium pump and the sodium-calcium exchanger.

The model also implemented equations to represent calcium induced calcium release and
calcium sequestration in the sarcoplasmic reticulum thereby incorporating intracellular events as
well. A notable attribute of the model was its conjecture that the sodium calcium stoichiometry
was actually 3:1 as opposed to the 2:1 neutral stoichiometry that had been widely accepted. This
new stoichiometry was necessary if the resting calcium were to be maintained at proper levels.
On the other hand, the model’s representation of calcium handling was flawed in that the calcium
transients were much higher than they were known to be.

8

Another ventricular cell model, The Luo-Rudy 2 model11 (Fig 1.5), utilized the current
experimental data at the time to study physiological events related to [Ca2+]i and the excitationcontraction coupling process. The Luo-Rudy 2 (LR2) model was a species specific model and
described the ventricular cell of the Guinea pig. The model used fifteen variables and included
an intracellular space to house the network sarcoplasmic reticulum (NSR) and junctional
sarcoplasmic reticulum (JSR) allowing the ability to investigate how intracellular calcium
dynamics affect several properties of the ventricular myocyte. Luo and Rudy were able to
replicate spontaneous Ca2+ release from the JSR and elucidate this spontaneous release’s
connection to early and delayed afterdepolarization as well as spontaneous rhythmic activity.

Figure 1.5 The Luo-Rudy Model. A schematic representation of the Luo-Rudy model11 with subcellular
compartments housing the junctional sarcoplasmic reticulum and the network sarcoplasmic reticulum.

Luo and Rudy also investigated conditions of maintained Ca2+ overload induced by a
suppressed INaK coupled with an application of a β-adrenergic agonist. Under these conditions
and pacing, the LR2 model renders triggered action potentials with decreasing coupling intervals
that yield to a steady state dynamic. Luo and Rudy explained this triggered activity to be a result
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of Ca2+ release from the sarcoplasmic reticulum. The LR2 model, as compared to some earlier
models, is an example of how detailed mathematical models are necessary to uncover and
explain some of the more complex interacting dynamics of cellular functions.
Jafri et al.12 and Winslow et al.13 developed the first models with local control of Ca2+induced Ca2+ release. The Jafri et al.12 model was developed for guinea pig, while Winslow et
al.13 developed a canine ventricular cell model (Fig 1.6) with the goal of assessing the average
functional change in the sodium-calcium exchanger and sarcoplasmic reticulum Ca2+. Motivated
by studies indicating strong similarities in the electrophysiology and the excitation coupling
processes among failing human hearts and canine tachycardia-induced heart failure, Winslow et
al. constructed their 33 variable model based on the work of the earlier guinea pig ventricular
cell model developed by Jaffri et al12. The model successfully replicated normal and failing midmyocardial action potentials as well as Ca2+ transients and showed that sarcoplasmic reticulum
downregulation and sodium-calcium exchanger upregulation have the most prominent effects on
action potential duration. Winslow et al. also noted that the prolonged plateau phase, hence
prolonged action potential duration, in failing mid-myocardial myocytes is due to an increased
inward current.
Based on their model results, Winslow et al. made the prediction that the mechanism for
the prolonged action potential duration was a decrease in the Ca2+ induced L-type Ca2+ current
inactivation resulting from a reduction of sarcoplasmic reticulum Ca2+ release. Predictions such
as this, as well as those that arise from other models are examples of how mathematical models
advance our understanding of complex dynamics and guide the need for future experiments.
Along with the advances in technology, particularly disease research and drug development and
the use of transgenic mouse experiments, Bondarenko et al.14 developed the first mouse
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ventricular myocyte model (Fig. 1.7). Bondarenko et al. used Markov models to represent the
functional structure of the sodium, L-type calcium, and the rapid delayed rectifier potassium
currents which allows the model to represent mutations that arise in the structure of these
currents and thus yielding varying phenotypes.

Figure 1.6 The Winslow-Rice Model. A schematic representation of the Winslow-Rice model12 with
components included to describe calcium-induced calcium release.

As action potential duration, shape, and ionic current contribution varies from species to
species and in different regions of the heart, the 44 variable Bondarenko model replicates the
characteristically short mouse action potential in the apical and septal regions, which differ in
four of the seven potassium currents (the rapidly recovering transient outward K+ current, the
slowly recovering transient outward K+ current, the ultra-rapidly activating delayed rectifier K+
current, and the non-inactivating steady-state voltage-activated K+ current), and their
contributing currents. In comparison to other species the mouse Ca2+ handling system is
relatively fast and the model accurately replicates experimentally observed Ca2+ fluxes. The
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molecular basis of the model and detailed characterization of localized intracellular calcium
dynamics renders the model the ability to replicate a multitude of “knock out” mouse
experiments which were increasingly being used in genetic research.

Figure 1.7 The Bondarenko et al. Model

1.3

Modelling Protein Signaling Pathways
All previous cardiac myocyte mathematical models were mostly devoted to the

mechanisms of the action potential generation and propagation, Ca2+ dynamics, and gating
properties of ionic currents. There were attempts to include the effects of the protein signaling
systems into those models by modifications of model parameters to simulate activation of the
system at the fixed stimulus strength15. However, these models were unable to provide
comprehensive descriptions of the activation of the signaling systems in a wide range of the
stimuli (agonist and antagonist concentrations). Therefore, most recent mathematical models of
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ventricular myocytes, in addition to the description of the action potential and Ca2+ dynamics,
incorporate protein signaling systems.
The ability of a myocyte to adapt to its environment and function accordingly relies on its
ability to communicate with its surroundings. This function is achieved through various cellular
signaling systems. Extracellular stimuli are detected by a multitude of receptors located on the
cell membrane which initiate and regulate many of the cellular responses to the cell’s
environment. Among the physiological responses to cell signaling in cardiac myocytes are the
regulation of heart rate and the excitation-contraction coupling process. Regulation of these and
other events are almost invariably inclusive of phosphorylation and/or dephosphorylation of
substrates via kinases and phosphatases respectively. Disruptions or modifications in one or
several components of complex signaling pathways generally results in disease. As such, an
understanding of the mechanisms that underlie these signaling paths has been an increasingly
important tool in the elucidation of the causal nature of and the discovery of novel treatments for
disease.
The most abundant cell receptors in cardiac myocytes are the G protein coupled receptors
(GPCRs). GPCRs include AT1 receptors, ET1B receptors, α- and β-adrenergic receptors which
are stimulated by angiotensin II, endothelin-1, epinephrine and norepinephrine, respectively.
Adrenergic receptors α and β are comprised of subtypes α1, α2, β1, β2, and β3, the most prevalent
in cardiac myocytes being the β1- and β2-adrenergic receptors which are studied here. The
activation process of GPCRs (Fig. 1.8) is initiated upon the binding of a Ligand to the receptor
on the membrane of the cell. This promotes a conformational change in the G-protein which has
alpha, beta, and gamma subunits attached. The alpha subunit which has a guanosine diphosphate
(GDP) molecule attached gains a phosphate and GDP is replaced with guanosine triphosphate
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(GTP). The active alpha subunit then detaches from the beta and gamma subunits. Inactivation
occurs when GTP loses a phosphate and rejoins the beta and gamma subunits allowing for the
process to be repeated.
The first models of the complete β1-adrenergic system for the ventricular myocyte were
developed by Saucerman et al.16 for rat ventricular myocytes. The model included the
electrophysiological and calcium handling components adapted from the Luo-Rudy 2 model11
and rabbit ventricular myocyte17 as well as the biochemical aspects of the signaling system. In
this first model, Saucerman et al.16 used only two protein kinase A (PKA) targets, the L-type
Ca2+ channels and phospholamban. As the β1-adrenergic system is a key effector in metabolism,
gene mutations 18,19,20, and cardiac myocyte contraction, Saucerman et al.16 used their model to
conduct a comparative study of the overexpression of β1-adrenergic receptors versus the
overexpression of adenylyl cyclase as it relates to myocyte contraction16.
Subsequently, the model was adapted to the rat ventricular myocyte21 to investigate the
gene mutation that results in the changes of β1-adrenergic regulation of the calcium dynamics. In
the second Saucerman et al. paper22, the model was developed for the β1-adrenergic signaling
system in rabbit ventricular myocytes, which included PKA-mediated regulation of the L-type
Ca2+ channels, phospholamban, troponin I, ryanodine receptors, and slow delayed rectifier K+
current. The model was applied to study the effects of KCNQ1-G589D gene mutation on the
action potential, Ca2+ dynamics, and arrhythmia development upon stimulation of the β1adrenergic signaling. Based on these two models16,22, another mathematical model of the β1adrenergic signaling system were developed for guinea pig23.
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Figure 1.8 The activation/inactivation of G protein receptors. Activation of G protein receptors occurs
when a ligand is bound to the receptor and the G protein couple with the receptor, undergoing a
conformational change which allows the guanosine diphosphate that is attached to the alpha subunit of
the G protein to gain a phosphate resulting in guanosine triphosphate. The alpha and beta-gamma
subunits are active and able to bind to other effectors. Inactivation occurs when the alpha, beta and
gamma subunits reattach to the G protein and a phosphate is loss from the guanosine triphosphate.

While the non-compartmentalized models contributed to our understanding of the role of
the β1-adrenergic system in cardiac myocytes on the whole cell level, more detailed models were
needed to elucidate further the effects of β-adrenergic stimulation on specific targets i.e.
phospholamban, troponin, ryanodine receptors, phospholemman, and several ion channels.
These targets are localized in different sub-cellular domains which effectively restricts
intracellular signaling.
Early compartmentalized models of the β1-adrenergic signaling system were developed
by Iancu et al.24,25. They included only the biochemical part of the β1-adrenergic and M2muscarinic signaling systems and described the dynamics of cAMP and PKA in different
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subcellular compartments (caveolar, extracaveolar, and cytosol). Further, Heijmann et al.26
developed a compartmentalized model of the canine ventricular myocyte to elucidate the effects
of this localization, particularly cAMP levels in sub-cellular compartments and their
contributions to whole cell cAMP levels, action potential and calcium transients.
More recently, a compartmentalized model of the β1-adrenergic signaling system was
developed for the mouse ventricular myocyte by Bondarenko27. Like the earlier mathematical
model, the Bondarenko model described the electrophysiological and biochemical aspects of the
ventricular myocyte. In addition, the Bondarenko model incorporated new experimental data
identifying localization of the two pools of the L-type Ca2+ channels, in the caveolar and
extracaveolar compartments. The model describes the individual contributions of each subset of
the L-type Ca2+ channel to the action potential and intracellular calcium transients, [Ca2+]i, along
with the contribution of other major ionic currents to the action potential, subcellular cAMP
dynamics, adenylyl cyclase and phosphodiesterase activation, and phosphorylation of protein
kinase A targets.
The advances made by the Bondarenko model include an explanation of the mechanisms
underlying prolonged action potential duration and increased intracellular calcium transients
upon β1-adrenergic stimulation in mouse ventricular myocyte. The model also predicts that
stimulation of the β1-adrenergic signaling system with isoproterenol at different frequencies
affects the intracellular calcium amplitude and action potential duration. Like models prior to it,
the Bondarenko model has its limitations. One of which is the absence of other myocyte
signaling pathways that may be interdependent with the β1-adrenergic signaling system,
particularly the β2-adrenergic and the CaMKII-mediated signaling systems. In this study we seek
to address the inclusion of the β2-adrenergic signaling system in the mouse ventricular myocyte.
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Mathematical models which represent biological phenomena have been an invaluable
tool in increasing our understanding of mechanisms that underlie many physiological outcomes.
The models of cardiac cells are no different. These models have aided in our understanding of
action potential generation and propagation, Ca2+ and Na+ dynamics, and arrhythmias as well as
the identification and investigation of potential therapeutic targets for treating diseases that arise
from disruptions or mutations in the topology of the cellular system.
1.4

Purpose of the Study
In this work, a compartmentalized model of the combined β1- and β2-adrenergic signaling

system is developed and an intuit of the effects of stimulation of β1- and β2-adrenergic receptors
individually and concurrently are sought. The interest to this topic is motivated by several
experimental findings that need to be explained by mathematical modeling. In addition, some
new model predictions can be generated by simulations and they can be verified or disproved
experimentally, leading to new more comprehensive mathematical ventricular myocyte models.
Experimental studies have shown remarkable differences in the physiological roles of the
β1- and β2-adrenergic signaling systems in cardiac cells. First, they respond differently to
stimulation by the same agonists and antagonists due to their different affinities. Secondly,
extended stimulation of β1-adrenergic receptors yields hypertrophic effects leading to heart
failure28, while modest increases in stimulation of β2-adrenergic receptors has cardio-protective
properties29. Thirdly, in some species, the effects of stimulation of β2-adrenergic receptors are
very small (rabbits, dogs, humans) or absent (mice), and cardiac myocytes need to be treated
with pertussis toxin, Gi protein inhibitor, to reveal physiological effects of the receptors. Finally,
mice overexpressing β2-adrenergic receptors were generated and demonstrated increased cardiac
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function at baseline conditions comparable to wild type littermates stimulated with maximal
concentrations of agonist isoproterenol.
Therefore, we developed a comprehensive mathematical model of the combined β1- and β2adrenergic signaling system to simulate their effects on the action potential, ionic currents, Ca2+
and Na+ dynamics in mouse ventricular myocytes. This specie is chosen as it is extensively used
in the experimental studies of the effects of overexpression and knock-out of the β1- and/or β2adrenergic receptors themselves and the components of the β1- and β2-adrenergic signaling
systems (G proteins, adenylyl cyclases, etc.). The model extensively verified by the experimental
data obtained predominantly from mice. Using this model, we were able to simulate the effects
of combined stimulation of both β1- and β2-adrenergic receptors, and their separate stimulation.
Our simulations demonstrated lack of the effects of stimulation of β2-adrenergic receptors under
control conditions; the effects of β2-adrenergic receptors were revealed upon inhibition of the
inhibitory G protein, Gi. We also developed a mathematical model for mouse ventricular
myocytes overexpressing β2-adrenergic receptors, simulated experimental findings on adenylyl
cyclase activity, protein kinase A activation, and the effects on action potential, ionic currents,
and Ca2+ dynamics. Our mathematical models can be used by the experimental scientists in the
field of cardiology to interpret their data, and for the development of mathematical models of the
combined β1- and β2-adrenergic signaling systems in other species.
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2

A MATHEMATICAL MODEL OF THE COMBINED β1- AND β2-ADRENERGIC
SIGNALING SYSTEM IN MOUSE VENTRICULAR MYOCYTES

2.1

Model Development
A mathematical model for the combined 1- and 2-adrenergic signaling system in mouse

ventricular myocytes (Fig. 2.1) is a natural extension of the previously published model for the 1adrenergic signaling system in mouse ventricular myocytes27,30. We incorporated a 2-adrenergic
signaling pathway in the Bondarenko model27 and simulated biochemical reactions, electrical
activity, Ca2+ and Na+ dynamics (see Appendix). Our model cell consists of three compartments
(caveolar (cav), extracaveolar (ecav), and cytosol (cyt); Fig. 2.1 and Appendix).
The localization of different signaling proteins and protein kinase A substrates in subcellular
compartments can be found in Fig. 2.1 and the Appendix and will be described below in the
corresponding chapters. In all compartments, the 1- and 2-adrenergic signaling systems are
activated by agonist (isoproterenol) (Fig. 2.1). Stimulation of 1-ARs activates Gs-mediated branch
which includes the subsequent stimulation of Gsα and Gsβγ subunits of Gs, adenylyl cyclases (AC47), which produce cyclic AMP. cAMP is hydrolyzed by phosphodiesterases (PDE2-4). cAMP
further activates protein kinase A which phosphorylates target proteins, among them are PDE3
and PDE4. Stimulation of 2-ARs activates both Gs- and Gi-mediated branches. Alpha subunits of
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Figure 2.1 A schematic representation of the combined β1- and β2-adrenergic signaling system of the
Mouse Ventricular Myocyte. A schematic representation of the combined β1- and β2-adrenergic signaling
systems in mouse ventricular myocytes. The cell consists of three compartments (caveolar, extracaveolar,
and cytosol) related to the combined β1- and β2-adrenergic signaling systems. The subspace volume (Vss)
is localized in the extracaveolar compartment. The biochemical portions of the combined β1- and β2adrenergic signaling systems are the β1-adrenergic receptors (β1-AR), the β2-adrenergic receptors (β2AR), the α-subunit of stimulatory G-protein (Gsα), the α-subunit of inhibitory G-protein (Giα), the βγsubunit of Gs and Gi (Gβγ), the adenylyl cyclases of type 5/6 or 4/7 (AC5/6 or AC4/7, respectively), the
phosphodiesterases of type 2, 3, or 4 (PDE2, PDE3, or PDE4, respectively), the cyclic AMP (cAMP),
regulatory (R) and catalytic (C) subunits of protein kinase A holoenzyme, the protein kinase A inhibitor
(PKI), the G-protein-coupled receptor kinase of type 2 (GRK2), the protein phosphatases of type 1 and
2A (PP1 and PP2A, respectively), the inhibitor-1 (I-1). Targets of the combined β1- and β2-adrenergic
signaling systems are in the caveolar (the fast Na+ current (INa), the L-type Ca2+ current (ICaL,cav), the
Na+/K+ pump (INaK) which is regulated by phospholemman (PLM), phosphodiesterases PDE2-PDE4, and
the time-independent K+ current (IK1)), the extracaveolar (the L-type Ca2+ current (ICaL,ecav), the rapidly
recovering transient outward K+ current (IKto,f), the ultrarapidly activating delayed rectifier K+ current
(IKur), ryanodine receptors (RyRs), and phosphodiesterases (PDE2, PDE4)), and cytosol (phospholamban
(PLB) and troponin I (TnI)). Stimulatory links are shown by black arrows and inhibitory links are shown
by red dashed lines with balls. Other transmembrane currents are the sarcolemmal Ca2+ pump (Ip(Ca)), the
Na+/Ca2+ exchanger (INaCa), the rapid delayed rectifier K+ current (IKr), the noninactivating steady-state
voltage activated K+ current (IKss), the Ca2+ and Na+ background currents (ICab and INab), which are not
affected by the combined β1- and β2-adrenergic signaling systems. The Ca2+ fluxes are uptake of Ca2+
from the cytosol to the network sarcoplasmic reticulum (NSR) (Jup) by the SERCA pump and Ca2+ release
from the junctional sarcoplasmic reticulum (JSR) (Jrel) through the ryanodine receptors. [Ca2+]i, [Na+]i,
and [K+] i are the intracellular Ca2+, Na+, and K+ concentrations in the caveolar, extracaveolar, and
cytosol; [Ca2+]o, [Na+]o, and [K+]o are the extracellular Ca2+, Na+, and K+ concentrations.
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Gs stimulate cAMP production by AC4-7 and Giα subunits inhibit AC activity, thereby contributing
to cAMP production by 1-AR pathway. Both 1-ARs and 2-ARs are phosphorylated by PKA
and G protein coupled receptor kinase of type 2 (GRK2). PKA is also regulated by heat-stable
protein kinase inhibitor (PKI). Phosphorylation is removed by two types of phosphatases, protein
phosphatase 1 and 2A. PKA target proteins are located in different compartments. The fast Na+
current, INa, 20% of the L-type Ca2+ channels (the L-type Ca2+ current, ICaL), the phospholemman,
which regulates the Na+-K+ pump, INaK, and the time-independent K+ current, IK1, are localized in
the caveolar compartment; the ultra-rapidly activating delayed rectifier K+ current, IKur, the rapidly
inactivating transient outward K+ current, IKto,f, 80% of the L-type Ca2+ channels, and the
ryanodine receptors, RyRs, are localized in the extracaveolar compartment; and phospholamban
and troponin I are localized in the cytosolic compartment. The detailed description of the model
development for the 1-adrenergic signaling system can be found elsewhere27,30. In this chapter,
we describe modifications of the model27 that result in a mathematical model of the combined β1and 2-adrenergic signaling system. We introduce a new "β1- and 2-adrenergic receptor module"
with two types of adrenoceptors and activation of Gs and Gi proteins and also modified the
"Adenylyl cyclase module" to account for the effects of Gi proteins on AC activity. The rest of the
model is the same as in reference 27. The resulting model of the combined β1- and 2-adrenergic
signaling system was verified by the experimental data (Figs. 3.1-3.6), and the model simulations
are presented in Figs. 3.7-3.19.
To develop a mathematical model we used experimental data mostly from mice and from
different laboratories to ensure that the model fits “average data”. The model has a modular
structure, starting from the "β1- and 2-adrenergic receptor module" and ending with the modules
that describe phosphorylation of PKA target proteins (ion channels, transporters, and proteins
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involved in Ca2+ dynamics). First, we adopted experimentally determined parameters for the
model, such as concentrations of β1- and β2-adrenoceptors, their affinities to agonists,
concentrations of G-proteins, etc. Then the simulation data of each module was fitted by the related
experimental data that describes activities of the major proteins involved (adenylyl cyclases,
phosphodiesterases, phosphatases, and others). Further, we simulated cAMP and PKA dynamics
and compared them to the experimental data in different compartments and in the cell as a whole.
The model parameters that were not measured experimentally or measured with low accuracy (the
rates of G-protein activation and hydrolysis, background adenylyl cyclase activities) were adjusted
to fit the output of the biochemical part of the model – cAMP and PKA dynamics. The
electrophysiological part of the model was from the Bondarenko model27.
2.2

β1- and 2-adrenergic receptor module
According to the experimental findings, the vast majority of 2-adrenergic receptors and Gi

proteins are located in caveolin-3-rich fractions, and most of the β1-ARs are localized in the
extracaveolar compartment20,31. The estimated total concentration of 1-ARs and β2-ARs in mouse
ventricular myocytes are 0.0103 M and 0.0053 M, respectively32. The total concentration of Gi
proteins was estimated based on the data of Rorabaugh et al.33 and is equal to 10.086 M while
the total concentration of Gs protein is equal to 2.054 M27. Therefore, in our model, we distribute
the 1-ARs almost evenly between the extracaveolar and cytosolic compartments, with only 1%
located in the caveolar compartment27. In contrast, the 2-ARs and Gi proteins almost completely
are localized in the caveolar compartment (99%), and only 1% of 2-ARs and Gi proteins are in
the extracaveolar compartment, as some small cAMP production upon stimulation of 2-ARs were
observed in the extracaveolar34. Such distribution of 2-ARs and Gi allowed us to obtain in the
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model cAMP transients in the caveolar, extracaveolar compartments and in the cell, which are in
line with the measurements of local cAMP concentrations in similar compartments in rat and
mouse ventricular myocytes34.
In the 1- and 2-adrenergic receptor module, the relatively fast ligand-receptor and G-proteinreceptor interactions, with time scales of tens milliseconds35, are described by algebraic equations
in steady-state approximation. The slower processes of G-protein activation, PKA- and GRK2mediated phosphorylation (hundreds of milliseconds; GRK2, G-protein-coupled receptor kinase
of type 2), and cAMP accumulation (hundreds of seconds) are described by ordinary differential
equations (see Appendix).
In order to derive algebraic equations which describe ligand-receptor and G-protein-receptor
interactions in the caveolar compartment (see Appendix), we first consider the mass conservation
laws for non-phosphorylated 1- and β2-adrenergic receptors and Gs-protein in that compartment:
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where [ R 1 ]cav
np ,tot is the total concentration of non-phosphorylated (np)  1-ARs in the caveolar
compartment, [ LR 1 ]cav
np is the concentration of  1-ARs with bound ligand L (concentration [L]),
cav
[ LR 1Gs ]np
is the concentration of 1-ARs with bound ligand L and stimulatory G-protein Gs,

cav
[ R 1Gs ]np
is the concentration of 1-ARs with bound Gs, [ R 1 ]cav
np , f is the concentration of free 1-

ARs, [ R 2 ]cav
np ,tot is the total concentration of non-phosphorylated 2-ARs in the caveolar
cav
compartment, [ LR 2 ]cav
np is the concentration of 2-ARs with bound ligand L, [ LR 2Gs ]np is the
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concentration of 2-ARs with bound ligand L and stimulatory G-protein Gs, [ R 2Gs ]cav
np is the
cav
concentration of 2-ARs with bound Gs, [ R 2 ]cav
is
np , f is the concentration of free  2-ARs, [Gs ]

the total concentration of the stimulatory G-protein Gs, and [Gs ]cav
f is the concentration of free Gs.
cav
cav
cav
cav
Concentrations of complexes [ LR 1 ]cav
np , [ LR 1Gs ]np , [ R 1Gs ]np , [ LR 2 ]np , [ LR 2Gs ]np , and

[ R 2Gs ]cav
np can be obtained from the steady-state approximation for the corresponding biochemical
reactions27, provided that the related dissociation constants are known. They are given by the
equations:
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Solving for the concentration of free, non-phosphorylated β1- and β2-adrenergic receptors
results in the following equations:
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Substituting the expressions for free non-phosphorylated β1- and β2-adrenergic receptors gives:
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As a result, we obtain a cubic equation in Gs  f with coefficients:

a 2,s  [ L]  K 1,H [ L]  K 2,H 
b 2,s  [ L]  K  1,H [ L]  K  2,H  [ R 1 ]np ,tot  [ R 2 ]np ,tot  

[ L]K  1,C K  1,H
 K  1,C K  1,H 
K  1,L




[ L]K  2,C K  2,H
 [ L]  K  2,H    K  2,C K  2, H 
K  2,L



[Gs ] [ L]  K  1,H [ L]  K  2,H 


[ L]K  2,C K  2,H
c 2,s  [ L]  K  1,H   K  2,C K  2,H 

K  2,L


[ L]  K



 2, H

  K


 1,C

K  1,H 


[ L]K  1,C K  1,H
 K  1,C K  1,H 
K  1,L



 [ L]  K  1, H  



 [ R 1 ]np ,tot  [Gs ]  


[ L]K  1,C K  1,H 
 [ R 2 ]np ,tot  [Gs ]  
K  1,L


[ L]K  2,C K  2,H
  K  2,C K  2,H 
K  2,L



[ L]K  1,C K  1,H
d  2,s  [Gs ]  K  1,C K  1,H 

K  1,L







[ L]K  2,C K  2,H
  K  2,C K  2,H 
K  2,L






28

[Gs]αβγ is determined from the mass conservation law for a given compartment:

[Gs ]cav
where [Gs ]

d [Gs ]

,GTP

,GTP

,GDP

[Gs ]cav,GTP

(2.17)

[Gs ]cav,GDP

are described by the ordinary differential equations:

[ R 2Gs ]np )

kact1,Gs ([ LR 1Gs ]np

[ LR 2Gs ]np )

khyd ,Gs [Gs ]

,GTP

(2.18)
,GDP

khyd ,Gs [Gs ]

dt
d [Gi ] ,GTP

kreas ,Gs [G ]

,GTP

kact 2,Gi [ R 2Gi ]PKA

dt
d [Gi ]

and [Gs ]

Vcell
Vcav

kact 2,Gs ([ R 1Gs ]np

dt

d [Gs ]

cav
fGs
[Gs ]tot

,GDP

khyd ,Gi [Gi ]

dt

,GTP

[Gs ]

,GDP

kact1,Gi [ LR 2Gi ]PKA

kreas ,Gi [G ]

[Gi ]

(2.19)

khyd ,Gi [Gi ]

(2.21)

,GDP

d [G ]

kact 2,Gs ([ R 1Gs ]np [ R 2Gs ]np ) kact1,Gs ([ LR 1Gs ]np [ LR 2Gs ]np )
dt
kact1,Gi [ LR 2Gi ]PKA kreas ,Gs [G ] [Gs ] ,GDP k reas ,Gi [G ] [Gi ] ,GDP

where [Gs ]

,GTP

and [Gs ]

,GDP

(2.20)

,GTP

kact 2,Gi [ R 2Gi ]PKA

are the concentrations of stimulatory G proteins with guanosine

triphosphate and guanosine diphosphate respectively attached to their alpha subunits. [Gi ]
and [Gi ]

,GDP

(2.22)

,GTP

are the concentrations of inhibitory G proteins with guanosine triphosphate and

guanosine diphosphate attached to their alpha subunits. [G ]

represents the concentration of

beta-gamma unit of G proteins. The constants kact1 and kact 2 are the rates at which ligand bound
β1- or β2-adrenergic receptors couple with stimulatory and inhibitory G proteins and non-ligand
bound β1- or β2-adrenergic receptors couple with both stimulatory and inhibitory G proteins.

khyd and kreas are the rates at which alpha subunits of stimulatory and inhibitory G proteins loose

29

or gain a phosphate. The subscripts np refers to the non-phosphorylated fraction and PKA refers
to the remaining protein kinase A phosphorylated fraction.
To solve the resulting cubic equation for non-negative roots we normalized the cubic
equation to the form:
x 3  px 2  qx  r  0; where p 

b 2,s

, q 

a 2,s

c 2,s
a 2,s

, and r 

d  2,s
a 2,s

.

By redefining coefficients to eliminate the quadratic term we obtain:
x 3  Ax  B; where A 

1
1
3q  ( p)2  and B 
2( p)3  9 pq  27r
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𝐴

Making Vieta’s substitution, 𝑥 = 𝑤 − 3𝑤 and then multiplying by w3 yields an equation which is
quadratic in form. The quadratic formula applied to this new equation yields solutions that can
be termed as:

 B
M  
 2



1/3


D 


1/3

 B

and N   
 D 
 2


where the discriminate D 

( A )3 ( B ) 2
.

27
4

Here, there are four possible cases.
Case 1: D > 0. Then y1  M  N ; y2 and y3 are complex conjugates.
Case 2: D = 0. Then y1  M  N ; y2  y3  ( M  N ) / 2;


( B )2 / 4 
Case 3: D < 0 and B > 0. Then   arccos  
 and
 (  A )3 / 27 



y1  2 

A
A
A
cos( ); y2  2 
cos(  2 / 3); y3  2 
cos(  4 / 3)
3
3
3

 ( B )2 / 4 
Case 4: D < 0 and B < 0. Then   arccos 
 and
 (  A )3 / 27 
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y1  2 

A
A
A
cos( ); y2  2 
cos(  2 / 3); y3  2 
cos(  4 / 3)
3
3
3

The solutions to the cubic equation are then wi  yi 

p
, i  1, 2,3, and
3

[Gs ] f  max{w1 , w3 , w3}

The graphs of the cubic function given by [Gs ] f for 0μM, 1μM and 10μM of the agonist
ligand Isoproterenol is shown in figure 2.2. The maximum solution ensures a positive value.
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Figure 2.2 The graph of the cubic function given by [Gs ] f for 0μM, 1μM and 10μM of
Isoproterenol
Because experimental data36 shows that interaction of non-phosphorylated β2-ARs occurs
predominantly with Gs protein and phosphorylated β2-ARs with Gi protein, we considered the mass
conservation laws for PKA phosphorylated β2-adrenergic receptors and Gi-protein in the caveolar
compartment (a similar derivation is done for the extracaveolar compartment):

[ R 2 ]cav
PKA,tot
[Gi ]cav

[ LR 2 ]cav
PKA

[ LR 2Gi ]cav
PKA

[ LR 2Gi ]cav
PKA
[ R 2Gi ]cav
PKA

[ R 2Gi ]cav
PKA
[Gi ]cav
f ,

[ R 2 ]cav
PKA, f ,

(2.23)
7)
(2.24)

8
where [ R 2 ]cav
PKA,tot is the total concentration of PKA-phosphorylated 2-ARs in the caveolar
)
cav
[
LR
G
]
compartment, [ LR 2 ]cav
is
the
concentration
of

-ARs
with
bound
ligand
L,
2
PKA
2 i PKA is the

(
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concentration of 2-ARs with bound ligand L and inhibitory G-protein Gi, [ R 2Gi ]cav
PKA is the
concentration of 2-ARs with bound Gi, [ R 2 ]cav
PKA, f

is the concentration of free PKA-

phosphorylated 2-ARs, [Gi ]cav is the total concentration of the inhibitory G-protein Gi, and [Gi ]cav
f
is the concentration of free Gi.
cav
cav
Concentrations of complexes [ LR 2 ]cav
PKA , [ LR 2Gi ]PKA , and [ R 2Gi ]PKA can be obtained from

the steady-state approximation for corresponding biochemical reactions:

[ LR 2 ]PKA 

[ L][ R 2 ]PKA, f

[ LR 2 Gi ]PKA 
[ R 2 Gi ]PKA 

(2.25)

K  2,L
[ L][ R 2 ]PKA, f [Gi ] f

(2.26)

K  2, A K  2,F

[ R 2 ]PKA, f [Gi ] f

(2.27)

K  2, A

cav
Substitution of the equations for [ LR 2Gi ]cav
PKA and [ R 2Gi ]PKA into equation (2.24) yields:

Gi 



 L  R 2  pka, f Gi  f
K  2,A K  2,F



 R 2 
Gi  f
pka , f
 Gi  f
K  2,A

(2.28)

and solution with respect to [Gi ]cav
f results in equation:

Gi  f

Gi 


1   R 2 

pka , f

 1
 L 



 K  2,A K  2,A K  2,F 

(2.29)

cav
cav
cav
Further substitution of the expressions for [ LR 2 ]cav
into
PKA , [ LR 2Gi ]PKA , [ R 2Gi ]PKA , and [Gi ] f

equation (2.23) results in equation:
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(2.30)

pka , f

Total PKA phosphorylated β2-adrenergic receptors is given by a differential equation,
however, here we can obtain an expression for the free PKA phosphorylated β2-adrenergic
receptors.
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Hence, the free PKA phosphorylated β2-adrenergic receptors is given by a quadratic equation
with coefficients:

a 2,i 

1
K  2,L

K

 2,L

  L  K  2, F   L

b 2,i  Gi   K  2,F   L   K  2, F   L   R 2 

pka ,tot

 K  2,A K  2,F  K  2,A K  2,F

 L
K  2,L

c 2,i    R 2 
K  2,A K  2,F
pka ,tot
Thus,
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b 2,i  b 2,i 2  4a 2,i c 2,i

(2.32)

2a 2,i

and

Gi  f

Gi 


1   R 2 
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 K  2,A K  2,A K  2,F 

(2.33)

where Gi  is a fraction of Gi tot and  R 2  pka ,tot is defined by the differential equation:

d [ R 2 ]PKA,tot
dt
2.3

kPKA

[C ] [ R 2 ]np ,tot

kPKA [ R 2 ]PKA,tot

(2.34)

Adenylyl cyclase module
Adenylyl cyclases regulate the synthesis of cAMP from ATP within the 1- and β2-adrenergic

signaling systems. Of the 10 isoforms of adenylyl cyclase known to be found in mammalian cells
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four of them are prominent in the 1- and β2-adrenergic pathway (AC4, AC5, AC6, and AC7) and
thus included in the model. AC5 and AC6, are localized in the caveolar while AC4 and AC7, are
localized in the extracaveolar37,38. Adenylyl cyclases AC4-AC7 are activated by the α-subunit of
G-protein, Gsα, and adenylyl cyclases AC5-AC6 are inhibited by the α-subunit of G-protein,
Giα37,39 (see Appendix). The adenylyl cyclases module for the combined 1- and β2-adrenergic
signaling systems is an extension of the adenylyl cyclase module presented in the previous
model27.

2.4

Electrophysiological part
The action potential of the mouse ventricular myocytes is described by the equation14,27:

dV
dt

1
( I CaL
Cm
I K1

I p ( Ca )
I Kur

I Kss

I NaCa
I Kr

I Cab
I Cl ,Ca

I Na

I Nab

I NaK

I Kto, f
(

I stim )
9)

where ICaL is the L-type Ca2+ current, Ip(Ca) is the sarcolemmal Ca2+ pump, INaCa is the Na+/Ca2+
exchanger, ICab is the Ca2+ background current, INa is the fast Na+ current, INab is the Na+
background current, INaK is the Na+-K+ pump, IKto,f is the rapidly recovering transient outward K+
current, IK1 is the time-independent K+ current, IKur is the ultrarapidly activating delayed rectifier
K+ current, IKss is the noninactivating steady-state voltage activated K+ current, IKr is the rapid
delayed rectifier K+ current, ICl,Ca is the Ca2+-activated chloride current, and Istim is the stimulus
current.
Four of the currents (ICaL, INa, IKto,f, and IKur) function as the substrates of the β1- and β2adrenergic signaling systems. In addition, there are three other phosphorylation substrates, which
are the major players in Ca2+ dynamics and are affected by the β1- and β2-adrenergic signaling
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systems: ryanodine receptors, phospholamban, and troponin I. In this chapter we will focus on two
major substrates that are affected by β2-ARs (the L-type Ca2+ current and phospholamban) for
which experimental data are available.

2.5

Model Simulations
This mathematical model of the combined β1- and β2-adrenergic signaling system contains

149 ordinary differential equations, multiple parameters and side conditions. It spans multiple
time scales ranging from microseconds (gating of ryanodine receptors) to tens of minutes (cAMP
accumulation and protein phosphorylation). Significant portions of the model include stiff
differential equations that describe exponentially growing and decaying processes.
We implemented the fourth-order Runge-Kutta method with a fixed time step for solutions
of the differential equations. A relatively large time step of 0.1 ms was used for simulations of
the model without electrical stimulation. To simulate electrical stimulation with a pulsed
stimulus current a time step of 0.0001 ms was used except for the first 10 milliseconds after
stimulation, where a time step of 0.000002 ms is used to account for the activation time constants
of the ryanodine receptors. This approach allowed us to optimize the accuracy and running time
of the simulations. In addition, we performed a sensitivity analysis of the model outputs with
respect to major model parameters and the initial conditions, as described below (see Chapter 3.3
Sensitivity Analysis).
Simulations of the model were run under a SUSE Linux 11 single processor platform on a
Dell Precision Workstation T3500 and was coded in FORTRAN 90. The workstation is powered
by a six-core Intel Xeon CPU with 12 GB RAM and 3.2 GHz. The cellular model is adjusted to a
room temperature of 298°K/25°C/77°F.
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3

DISTINCT PHYSIOLOGICAL EFFECTS OF 1- AND 2-ADRENOCEPTORS IN
MOUSE VENTRICULAR MYOCYTES: INSIGHTS FROM A
COMPARTMENTALIZED MATHEMATICAL MODEL

3.1

Introduction
Experimental data on stimulation of β1-ARs from different laboratories consistently shows a

robust increase in protein kinase A (PKA) activity; phosphorylation of ion channels, regulatory
and contractile proteins; increase or decrease in ionic currents that shape action potential; and a
robust increase in intracellular Ca2+ transient ([Ca2+]i) (see27 and refs therein). However, the
experimental picture of stimulation of β2-ARs is less consistent. Some of the experimental data
shows that the activation of β2-ARs does increase cAMP concentration, significantly activates
PKA, increase the magnitude of the L-type Ca2+ current, and phosphorylation of regulatory
proteins (phospholamban) in multiple species34,40,41,42. Some other experiments on the stimulation
of β2-ARs do not produce physiological effects, in particular, in mouse ventricular myocytes or
mouse hearts43,44. Therefore, specific experimental protocols were employed to reveal the
physiological effects of β2-ARs in the mouse hearts to suppress inhibitory Gi-mediated pathway
branch or to inhibit phosphodiesterase activity41,42. Further, the interpretation of the experimental
data on activation of β2-ARs becomes even more complicated due to the use of different agonists,
β2-AR specific agonist zinterol or combination of isoproterenol and β1-AR specific inhibitor
CGP20712A. In particular, the use of 1 μM zinterol in the experiments, which the half-activation
constant for β1-ARs is around 1 - 3 μΜ45,46, can produce significant contribution to the effects of
β1-ARs in addition to the β2-ARs.
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As there is no mathematical model that describes the effects of β1- and β2-ARs in mouse
ventricular myocytes, we developed and explored a compartmentalized mathematical model of
mouse ventricular myocytes that includes both the β1- and β2-adrenergic signaling systems to
describe the effects of stimulation of β1- and β2-ARs on the behavior of cardiac cells. The model
is based on the previously developed mathematical model of the β1-adrenergic signaling system in
mouse ventricular cells, which was extensively verified by the experimental data on the activation
of β1-ARs27,30. The model27 was also recently used by Esprito Santo et al.47 for simulation of the
larger susceptibility of the isoproterenol-stimulated mouse cardiac cells to DADs with INaCa
overexpression. We only added β2-ARs activation module in the β1- and β2-adrenergic pathways
before the module of cAMP production/degradation and modified adenylyl cyclase module to
include the effects of Gi, which were validated by the thorough experimental data on interaction
between β1- and β2-ARs and cAMP dynamics in different compartments in mice34 as outlined
below. The model was investigated using simultaneous stimulation of both β1- and β2-ARs, and
separate stimulation of β1-ARs or β2-ARs by isoproterenol. The model successfully reproduced
existing experimental data on the activation of β1- and/or β2-ARs, adenylyl cyclase activity, the
effects of Gi and PDE3/PDE4 inhibition on cAMP dynamics, ionic currents, [Ca2+]i transients.
Particular attention is paid to the effects of stimulation of β2-ARs on cAMP and PKA dynamics,
phosphorylation of phospholamban (PLB), the magnitude of the L-type Ca2+ current, action
potentials, and [Ca2+]i dynamics. We found that the separate stimulation of the β2-ARs under
normal physiological conditions does not affect action potential and [Ca2+]i transients. The
physiological effects β2-ARs are revealed upon inhibition of Gi protein (by pertussis toxin (PTX))
or phosphodiesterases of type 3 and 4 (PDE3 and PDE4). The model also made testable predictions
on the changes in the action potential, magnitudes of [Ca2+]i and [Na+]i fluxes, the rate of decay of
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[Na+]i concentration upon both combined and separate stimulation of β1- and β2-ARs, and the
contribution of phosphorylation of PKA targets to the changes in the action potential and [Ca2+]i
transient. Mechanisms of the changes are disclosed by the simulations, sensitivity of the simulation
data to the changes of the concentrations of the major signaling proteins is investigated, and the
model limitations are discussed.

3.2

Results

3.2.1 Adenylyl cyclase activity
In the combined 1- and β2-adrenergic pathways, adenylyl cyclases are responsible for the
synthesis of cAMP from ATP. Figure 3.1A shows experimental data on activation of AC5 and
AC6 by Gsα by Chen-Goodspeed et al.48 and the corresponding simulation data using our model
for AC5/6 activation at different concentrations of Giα (activation of AC4/7 is the same as in the
model27 and is not shown). In Fig 3.1A, simulated data shows a right-handed Giα concentrationdependent shift of the activation curves when AC5/6 activity is normalized to the maximum at Gsα
= 10 µM. In addition, Giα subunit inhibits maximum AC5/6 activity at Gsα = 10 µM when
normalized to the maximum activity at Giα = 0 µM (Fig. 3.1B). In Fig. 3.1C, simulation data on
inhibition of AC5/6 by Giα is compared to the experimental data for AC6 at different values of
Gsα48. The figure demonstrates good agreement between experimental and simulated results.
Adenylyl cyclase activity can also be used as an indicator of desensitization of 1- or 2ARs. Experimental data on AC activity upon stimulation of 1- or 2-ARs as functions of
isoproterenol concentration were obtained by Freedman et al.49 at three time moments (at the
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Figure 3.1 Normalized activity of adenylyl cyclases as functions of Gsα and Giα. Panel A: Experimental
normalized activity of AC5 (filled circles) and AC6 (unfilled circles) as functions of Gsα48. Simulated data
for normalized activity of AC5/6 for different concentrations of Giα are shown by a solid line (Giα = 0.0
μM), long dashed line (Giα = 0.01 μM), medium dashed line (Giα = 0.1 μM), short dashed line (Giα = 1.0
μM), and dotted line (Giα = 3.0 μM). Each simulated data on AC5/6 activity for different concentration of
Giα is normalized by its maximum value. Panel B: Simulated data for normalized activity of AC5/6 for
different concentrations of Giα are shown by a solid line (Giα = 0.0 μM), long dashed line (Giα = 0.01
μM), medium dashed line (Giα = 0.1 μM), short dashed line (Giα = 1.0 μM), and dotted line (Giα = 3.0
μM). Each simulated data on AC5/6 activity for different concentration of Giα is normalized by the
maximum AC5/6 activity at Giα = 0.0 μM. Panel C: Experimental normalized activity of AC6 (symbols) as
functions of Giα at different values of Gsα48. Simulated data for normalized activity of AC5/6 for different
concentrations of Gsα are shown by a gray dotted line (Gsα = 0.01 μM), gray dashed line (Gsα = 0.02 μM),
gray solid line (Giα = 0.1 μM), black dotted line (Gsα = 0.25 μM), black dashed line (Gsα = 1.0 μM), and
black solid line (Giα = 6.0 μM). Each simulated data on AC5/6 activity for different concentration of Gsα
is normalized by its maximum value.
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maximum activity (from 50th to 75th seconds, depending on isoproterenol concentration), 5th min,
and 30th min). It is shown that the AC activity decreases in time, reflecting desensitization of 1ARs or 2-ARs (symbols in Fig. 3.2A and 3.2B). Simulation data also demonstrates the decrease
in AC activity as functions of time at different concentrations of isoproterenol (solid, dashed, and
dash-dotted lines in Fig. 3.2A and 3.2B). Two mechanisms are responsible for the desensitization
of 1-ARs or 2-ARs: phosphorylation by PKA and GRK2.
We also simulated the effects of different concentrations of isoproterenol on adenylyl cyclase
activity in mouse ventricular myocytes (Fig. 3.2C). Experimental data on total AC activity in
mouse ventricles and cardiac cells as a function of isoproterenol concentration after 10-min
exposures are shown by unfilled50 and filled circles51 with error bars. Simulation data on the total
AC activity after a 10-minute exposure to different concentrations of isoproterenol, when both
1- and 2-ARs are stimulated are shown by a solid line. Thus, our model was able to reproduce
absolute values of the total cellular AC activity as a function of isoproterenol (Fig. 3.2C).
It was also interesting how much inhibition of Gi protein affects AC activity in mouse ventricular
cells. For this purpose, Akhter et al.52 compared AC activity in the cells upon stimulation with 100
µM isoproterenol without and with exposure to PTX. It was shown experimentally (black bars
with error marks in Fig. 3.2D) that there is a trend toward an increase in AC activity upon inhibition
of Gi. Our simulations reproduced this effect, when both 1- and 2-ARs are stimulated by 100 µM
isoproterenol (gray bars in Fig. 3.2D).
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Figure 3.2 Desensitization of β1- and β2-adrenoceptors. Panels A and B show increases in adenylyl
cyclase activity above basal level (%) are measured at maximum (from 50th to 75th seconds, control, filled
circles) and at two time moments (5 min and 30 min, unfilled circles and unfilled squares, respectively)
after exposure to different concentrations of isoproterenol49. The corresponding simulated data on the
normalized AC activity for the maximum, 5-minute, and 30-minute delays are shown by solid, dashed, and
dash-dotted lines, respectively. Data for β1-ARs and β2-ARs are obtained with the block of β2-ARs and β1ARs, respectively. Panel C: Adenylyl cyclase activity as a function of isoproterenol. Experimental data on
AC activity (in pmol/mg/min) in mouse hearts and ventricular myocytes obtained after 10-minutes
exposure to isoproterenol are shown by unfilled circles50 and filled circles51. The solid line shows
corresponding simulated AC activity at different concentrations of isoproterenol upon activation of both
β1-ARs and β2-ARs. Panel D: The effects of PTX on adenylyl cyclase activity. Experimental data on AC
activity (in pmol/mg/min) in myocardial membranes are obtained after 15-minutes exposure to 100 μM
isoproterenol without and with application of PTX and are shown by black bars with error bars52. The
corresponding simulated data are shown by gray bars when both β1-ARs and β2-ARs are activated.
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3.2.2 Protein kinase A activation
Generated by adenylyl cyclases, cAMP molecules activate protein kinase A, a major signaling
molecule in the 1- and 2-adrenergic signaling system which phosphorylates signaling proteins,
ion channels, and proteins regulating Ca2+ dynamics. Figure 3.3A shows PKAI (circles) and PKAII
(squares) activity as functions of cAMP concentrations obtained from experimental data53,54. Our
simulations displayed by a solid (PKAI) and a dashed (PKAII) line, respectively, fit well to the
experimental data. We also simulated the cellular PKA activity ratio in control and upon
stimulation of the combined 1- or 2-adrenergic signaling system, separate stimulation of the 1or 2-adrenergic signaling, and the 2-adrenergic signaling in the cells pretreated by PTX with 1
µM isoproterenol (Fig. 3.3B). We performed four simulations for this figure: no
isoproterenol/basic cAMP level (−cAMP), no isoproterenol/3 µM cAMP (+cAMP), 1 µM
isoproterenol/no externally applied cAMP (−cAMP), and 1 µM isoproterenol/3 µM cAMP
(+cAMP). Then, the corresponding PKA(−cAMP)/PKA(+cAMP) ratios were calculated. The
simulations of the stimulation of the combined 1- or 2-adrenergic signaling system and a separate
stimulation of the 1-adrenergic signaling compare well to the experimental data for similar
experimental conditions in the rabbit hearts (black bars55). However, separate stimulation of the
2-adrenergic signaling system with 1 µM isoproterenol alone lead to very little activation of PKA
(10% increase compared to control). A significantly larger increase in PKA activation (39%
increase) is observed upon stimulation by 1 µM isoproterenol plus PTX (Fig. 3.3B). This
simulation result explains one of the mechanisms by which the effects of the 2-adrenergic
signaling system are revealed in the experiments - by the inhibition of Gi protein.
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Figure 3.3 Protein kinase A activity. Panel A: PKA I and PKA II activity as functions of cAMP.
Experimental data for PKA I are obtained by two methods by Dao et al.54 and are shown by filled and
unfilled circles; data for PKA II is obtained by Beavo et al.53. The corresponding simulated data are
shown by a solid (PKA I) and a dashed (PKA II) line. Panel B: PKA activity ratio. Experimental data
(black bars with error) were obtained without (−cAMP) and with (+cAMP) an externally applied 3 µM
cAMP, both without and with 1 µM isoproterenol (black bars55). We also performed four simulations: no
isoproterenol/basic level cAMP (−cAMP), no isoproterenol/3 µM cAMP (+cAMP), 1 µM
isoproterenol/no externally applied cAMP (−cAMP), and 1 µM isoproterenol/3 µM cAMP (+cAMP).
Then, the corresponding PKA ratios were calculated. Simulations were performed for four cases:
activation of both β1-ARs and β2-ARs, activation of β1-ARs alone, activation of β2-ARs alone, and
activation of β2-ARs alone with the inhibition of Gi (PTX).

44

3.2.3 Compartmentalized cAMP and PKA dynamics
cAMP concentration displays different dynamics in the three major cellular compartments. It
is determined by the balance between cAMP production by adenylyl cyclases, cAMP degradation
by phosphodiesterases, and cAMP diffusion between intracellular compartments. Figure 3.4 shows
the simulated time courses of cAMP concentrations in different subcellular compartments in
response to 1 M isoproterenol under four different conditions: stimulation of the combined β1and β2-adrenergic signaling systems, β1-adrenergic signaling system alone, β2-adrenergic signaling
system alone, or β2-adrenergic signaling system alone with prior exposure to PTX. Stimulation of
the combined β1- and β2-adrenergic signaling systems or β1-adrenergic signaling system alone
results in a significant and similar increase of cAMP production by adenylyl cyclases and cAMP
degradation by phosphodiesterases in the caveolar, extracaveolar, and cytosolic compartments, as
well as in the whole cardiac cell (Fig. 3.4 A-D, red and green lines). Stimulation of the β2adrenergic signaling system alone shows a smaller but significant increase only in the caveolar
compartment with virtually no change in the extracaveolar and cytosolic compartments and the
whole cell (Fig. 3.4A-D, cyan lines). However, a much larger increase in cAMP production is
obtained during stimulation of β2-ARs with PTX (Fig. 3.4A-D, blue lines). The greatest, multifold
increase is observed in the caveolar compartment (Fig. 3.4A), and a smaller, but noticeable
increase is found in the extracaveolar and cytosolic compartments and the whole cell (Fig. 3.4BD).
The behavior of the catalytic subunit of PKA is similar to that for cAMP (Fig. 3.5). Stimulation
of the combined β1- and β2-adrenergic signaling systems or β1-adrenergic signaling system alone
lead to a large similar increase of PKA activity in all three compartments and in the whole cardiac
cell (Fig. 3.5A-D, red and green lines). Stimulation of β2-ARs alone produces quite a significant
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effect on PKA activity only in the caveolar compartment (Fig. 3.5A-D, cyan lines). Inhibition of
Gi by PTX upon stimulation of β2-ARs significantly enhances the response in the caveolar, but the
effects in other compartments are still quite small (Fig. 3.5A-D, blue lines).

Figure 3.4 cAMP dynamics in mouse ventricular myocytes. Simulated cAMP concentrations are shown
as functions of time in the caveolar (Panel A), extracaveolar (Panel B), and cytosolic compartments
(Panel C), as well as in the whole cell (Panel D). Simulations were performed for four cases: activation
of both β1-ARs and β2-ARs, activation of β1-ARs alone, activation of β2-ARs alone, and activation of β2ARs alone with the inhibition of Gi (PTX). Data in Panels A-D are obtained upon application of 1 µM
isoproterenol.
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Figure 3.5 PKA catalytic subunit dynamics in mouse ventricular myocytes. Simulated PKA catalytic
subunit concentrations are shown as functions of time in the caveolar (Panel A), extracaveolar (Panel B),
and cytosolic compartments (Panel C), as well as in the whole cell (Panel D). Simulations were performed
for four cases: activation of both β1-ARs and β2-ARs, activation of β1-ARs alone, activation of β2-ARs alone,
and activation of β2-ARs alone with the inhibition of Gi (PTX). Data in Panels A-D was obtained upon the
application of 1 µM isoproterenol.

We compared simulated cAMP production in different compartments and in the whole cell
with the experimental data by Nikolaev et al.34. Nikolaev et al.34 used a fluorescence resonance
energy transfer (FRET) based cAMP sensor to measure local cAMP concentrations in different
regions of the ventricular myocytes upon stimulation of the β1- and β2-adrenergic signaling
systems. Figure 3.6A shows a comparison of the simulated and the experimental data on cAMP
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production upon separate stimulation of β1-ARs and β2-ARs in caveolar and extracaveolar
compartments. It is seen that the stimulation of β1-ARs in both compartments significantly
increases cAMP production; however, the stimulation of β2-ARs demonstrates only a tiny increase
of cAMP in the extracaveolar and a significant, but smaller than for β1-ARs, increase in cAMP in
the caveolar compartment. On the whole cell level, simultaneous stimulation of β1-ARs and β2ARs or β1-ARs alone produces quite a large magnitude of cAMP transient, while the effect of the
stimulation of β2-ARs alone is quite small (Fig. 3.6B). Simulation results satisfactorily reproduced
the experimental observations (Fig. 3.6A, B).

3.2.4 The effects on the L-type Ca2+ current
Experimental data on mouse ventricular myocytes shows that the application of 1 µM
isoproterenol, which stimulates both β1-ARs and β2-ARs, robustly increases the magnitude of the
L-type Ca2+ current by about 2 folds41,56,57,58. Stimulation of β1-ARs alone with 1 µM isoproterenol
and a block of β2-ARs by 50 nM ICI-118551 results in a similar increase in the magnitude of ICaL41.
Further, application of 1 µM of isoproterenol with β1-ARs blocked with 0.3 µM of CGP-20712A41
or application of PTX without stimulation of β1-ARs or β2-ARs43,58,59 does not show any effect on
ICaL, demonstrating silence of the β2-adrenergic signaling system under these experimental
conditions. However, the small effects of β2-ARs can be revealed by stimulating β2-ARs with 1
µM isoproterenol and additional application of PTX58 or with inhibition of PDE3 and PDE441.
Figure 3.7 shows simulations of these experimental findings. Application of PTX does not
demonstrate any effect on ICaL when both β1-ARs and β2-ARs are intact (compare solid line for
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Figure 3.6 Compartmentalization of cAMP dynamics in mouse ventricular myocytes. Panel A:
Experimental data on normalized cAMP concentration in mouse ventricular myocytes in caveolar and
extracaveolar compartments upon selective stimulation of β1-ARs and β2-ARs are shown by black bars34;
the corresponding simulation data is shown by gray bars. Panel B: Experimental data on normalized
cAMP concentration in mouse ventricular myocytes (whole cell concentrations) upon stimulation of both
β1-ARs and β2-ARs, β1-ARs alone, or β2-ARs alone are shown by black bars34; the corresponding
simulation data is shown by gray bars.

49

control and long-dashed line for PTX in Fig. 3.7A). Stimulation of both β1-ARs and β2-ARs by 1
µM isoproterenol increases the magnitude of ICaL by 1.9 folds (compare solid line for control and
small-dashed line for 1 µM isoproterenol in Fig. 3.7A and Fig. 3.8C for the experimental data).
An additional application of PTX to 1 µM isoproterenol slightly increases the amplitude of ICaL to
reflect the effects of β2-ARs (dotted line in Fig. 3.7A). Finally, the magnitude of ICaL shows a larger
increase upon application of 1 µM isoproterenol with inhibition of PDE3 and PDE4 (dashed-dotted
line in Fig. 3.7A). To reveal the contribution of β1-ARs and β2-ARs to the total effects, we
performed simulations with the same protocols, but with inhibition of β2-ARs or β1-ARs. The
results are shown in Figs. 3.7, B and C). The effects of stimulation of β1-ARs with 1 µM
isoproterenol and a block of β2-ARs are very similar to those when both β1-ARs and β2-ARs are
intact (Fig. 3.7B). The only difference is that no effects of PTX are observed.
In contrast, only small increases in the magnitudes of ICaL are observed upon stimulation of β2ARs when β1-ARs are blocked under different experimental conditions (Fig. 3.7C). The
application of PTX did not change the magnitude of ICaL (compare solid line for control and longdashed line for PTX in Fig. 3.7C). Stimulation of β2-ARs when β1-ARs are blocked with 1 µM
isoproterenol leads to a tiny increase in ICaL (3% increase), which virtually cannot be detected in
the experiments (compare solid line for control and small-dashed line for 1 µM isoproterenol in
Fig. 3.7C). Application of 1 µM isoproterenol in the presence of PTX results in a larger increase
in ICaL (12% increase, dotted line in Fig. 3.7C). Even larger effects of stimulation of β2-ARs are
obtained upon application of 1 µM isoproterenol and inhibition of PDE3 and PDE4 (22% increase,
dashed-dotted line in Fig. 3.7C).
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Figure 3.7 The effects of stimulation of β1-ARs and β2-ARs on the L-type Ca2+ current. Simulated currentvoltage relationships obtained upon the stimulation of both β1-ARs and β2-ARs (Panel A), β1-ARs alone
(Panel B), and β2-ARs alone (Panel C). Currents are obtained by voltage pulses from −70 mV to +50 mV
(in 10-mV increments) from a holding potential of −80 mV and without Ca2+-induced Ca2+ release to
account for heavy buffering conditions. Simulations were performed for several physiological conditions:
control (solid lines), inhibition of Gi without isoproterenol (long dashed lines, they are almost invisible in
figures due to very tiny effects), after application of 1 μM isoproterenol (medium dashed lines), after
application of 1 μM isoproterenol with inhibition of Gi (dotted lines), or after application of 1 μM
isoproterenol with inhibition of PDE3 and PDE4 (dash-dotted lines).

Comparisons of the simulated and experimental data under different experimental conditions
is shown in Fig. 3.8. No effect is observed in simulations and in the experiments43,59 upon
application of PTX (Fig. 3.8A). A small increase in the magnitude of ICaL is observed upon
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application of 1 µM isoproterenol without and with PTX in simulations and in the experiment by
Xu et al.58 (Fig. 3.8B). The statistically significant effects of stimulation of β2-ARs alone
(37%±13% increase) is observed upon application of 1 µM isoproterenol and inhibition of PDE3
and PDE4 (by cilostamide and rolipram, respectively), which is close to our simulated effect under
similar experimental conditions (third set of bars in Fig. 3.8C). However, as expected, stimulation
of β1-ARs alone with 1 µM isoproterenol and inhibition of PDE3 and PDE4 results in a much
larger increase in ICaL (two last bars in Fig. 3.8C), which was also predicted by our simulations.
Thus, our model for the first time provides non-contradictive simulated data on the effects of
β1-ARs and β2-ARs on the L-type Ca2+ current in mouse ventricular myocytes. Simulations show
that the effects of β2-ARs on the L-type Ca2+ current can be revealed by stimulation with
isoproterenol with additional inhibition of Gi or PDE3 and PDE4.

3.2.5 The effects on phospholamban
Similar to the L-type Ca2+ current, stimulation of both β1-ARs and β2-ARs or β1-ARs alone
with 10 µM isoproterenol results in a multifold increase of the relative phosphorylation level of
phospholamban (which regulates SERCA pump activity) compared to control levels in both
simulations (4.9 and 5.6-fold increase) and in the experiment with β2-AR knockout mice (3.6-fold
increase) (Fig. 3.9A). This isoproterenol concentration is chosen to compare simulations with
corresponding experimental data by Soto et al.60, for which simulation data are similar to the
experimental findings. Inhibition of Gi, which mimics application of PTX, does not affect the
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Figure 3.8 A comparison of the experimental and simulated data on the L-type Ca2+ current. A
comparison of the experimental and simulated data on the L-type Ca2+ current at different physiological
conditions in mouse ventricular myocytes upon stimulation of both β1-ARs and β2-ARs. Panel A: PTX
(inhibition of Gi) does not cause any effect on the magnitude of the L-type Ca2+ current in the simulation
(black bar) and in experiments (gray bars by Zhou et al.59 and dark gray bars by Heubach et al.43). Panel
B: The increase in magnitude of the L-type Ca2+ current upon stimulation with 1 μM isoproterenol
without and with the inhibition of Gi by PTX. Simulated data are shown with black bars; experimental
data by Xu et al.58 are shown by gray bars with errors. Panel C: An increase in peak ICaL under different
physiological conditions (control, application of 1 μM isoproterenol, application of 1 μM isoproterenol
with inhibition of β1-ARs and PDE3 and PDE4, or application of 1 μM isoproterenol with inhibition of β2ARs and PDE3 and PDE4). Experimental data on the application of 1 μM isoproterenol are obtained
from Sako et al.57, Kim et al.56, and Timofeev et al.41; experimental data on application of 1 μM
isoproterenol with inhibition of β1-ARs and PDE3 and PDE4 and application of 1 μM isoproterenol with
inhibition of β2-ARs and PDE3 and PDE4 are obtained from Timofeev et al.41.

53

phosphorylation level of phospholamban. An application of 10 µM isoproterenol with inhibition
of Gi demonstrates similar effects as without Gi inhibition (Fig. 3.9A). This phospholamban
behavior is different from the L-type Ca2+ current (the last is affected by Gi inhibition) and is
explained by the localization of phospholamban in the cytosolic compartment, where the effects
of β1-ARs are predominant.
Activation of β2-ARs alone, with inhibition of β1-ARs, shows a different behavior (Fig.
3.9B). Inhibition of Gi with PTX and without application of isoproterenol does not affect PLB
phosphorylation in simulations and in the experiments with β1-AR knockout mice60,61.
Simulations also show a 57% increase in PLB phosphorylation upon stimulation of β2-ARs alone
with 10 µM isoproterenol. This is in line with the trend in the experimental data, where PLB
phosphorylation increased by 1.8-2.3 times upon application of 10 µM isoproterenol in β1-AR
knockout mice; however, experimental data did not conclude a significant difference. Finally,
stimulation of β2-ARs alone with 10 µM isoproterenol and upon inhibition of Gi results in a
multifold increase of PLB phosphorylation both in simulations (9-fold increase comparing to
control) and in the experiments with β1-AR knockout mice (3-3.7-fold increase) (Fig. 3.9B).
Note that even larger relative increase in PLB phosphorylation are obtained upon stimulation of
β2-ARs with zinterol in rats62 (Fig. 3.9B). While the stimulation of β2-ARs alone leads to a larger
relative increase in PLB phosphorylation compared to the stimulation of β1-ARs alone, the
absolute level of PLB phosphorylation is significantly larger during stimulation of β1-ARs
(100% PLB phosphorylation) than β2-ARs (35% PLB phosphorylation).
Therefore, our model demonstrated that the effects of β2-ARs on phospholamban can be
revealed by stimulation with isoproterenol with an additional inhibition of Gi.
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Figure 3.9 Phosphorylation of phospholamban in mouse ventricular myocytes upon stimulation of β1-ARs
and β2-ARs. Panel A: Activation of both β1-ARs and β2-ARs or β1-ARs alone. Experimental data on PLB
phosphorylation by Soto et al.60 (black bars with errors) are obtained upon application of 10 μM
isoproterenol. Simulation of activation of both β1-ARs and β2-ARs (gray bars) or β1-ARs alone (dark gray
bars) are shown for control, after inhibition of Gi by PTX, after application of 10 μM isoproterenol, or
application of 10 μM isoproterenol with inhibition of Gi by PTX. Panel B: Activation of β2-ARs alone.
Experimental data on PLB phosphorylation by Soto et al.60 (black bars with errors) and Liu et al.61 (gray
bars with errors are obtained in mice for control, after incubation with PTX, upon application of 10 μM
isoproterenol, and upon application of 10 μM isoproterenol and incubation with PTX. Experimental data
on PLB phosphorylation by Kuschel et al.62 (dark gray bars with errors) are obtained in rats for control,
after incubation with PTX, upon application of 10 μM zinterol, and upon application of 10 μM zinterol
and incubation with PTX. Simulation of activation of β2-ARs alone (light gray bars) are shown for
control, after inhibition of Gi by PTX, after application of 10 μM isoproterenol, or application of 10 μM
isoproterenol with inhibition of Gi by PTX.
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3.2.6 The effects on mouse action potential and ionic currents
Experimental data obtained from mouse ventricular myocytes shows that the application of
near-saturating doses of isoproterenol (1 to 2 µM) results in prolongation of the action potential
duration at 50% and 90% repolarization27. To simulate these and other effects, we stimulated the
model cell with current pulses (Istim = 80 pA/pF, stim = 1.0 ms) with the frequency 1 Hz for 300 s
when both β1-ARs and β2-ARs are available, or β2-ARs blocked, or β1-ARs blocked. Simulations
were performed under several physiological conditions: control; application of 1 µM
isoproterenol; inhibition of Gi (PTX application); application of 1 µM isoproterenol and PTX;
PDE3 and PDE4 inhibition; and application of 1 µM isoproterenol and PDE3 and PDE4 inhibition.
The effects of 1 µM isoproterenol on the APDs when both β1-ARs and β2-ARs are stimulated or
only β1-ARs are stimulated are very similar, and the effects of the stimulation of β1-ARs are studied
in detail previously (see Fig. 23 and Table 1 in Ref. 27). They demonstrated that the application
of 1 µM isoproterenol affected APDs at all levels of repolarization (25%, 50%, 75%, and 90%;
see also Table 1 in this paper). In contrast, the stimulation of β2-ARs with 1 µM isoproterenol,
when β1-ARs are blocked, affects mostly the later phases of repolarization (APD75 and APD90),
and the effects of β2-ARs can be revealed upon application of PTX or inhibition of PDE3,4 (see
Fig. 1A and Table 1).

Figure 3.10 shows mouse action potentials for control conditions and after application of 1 µM
isoproterenol in the PTX-pretreated myocytes when β1-ARs are blocked. In this case, APD25 does
not change at all, and the
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Table 1 Action potential durations (in ms) upon stimulation of both β1-ARs and β2-ARs, β1-ARs
alone, and β2-ARs alone under different physiological conditions
APD25
APD50
APD75 APD90
β1- & β2-ARs
Control
1.7
3.3
9.35
26.15
Isoproterenol 1 µM
1.8
3.8
11.1
30.00
PTX
1.7
3.2
9.35
26.15
PTX + Isoproterenol 1 µM
1.8
3.8
11.6
32.35
PDE3,4 inhibition
1.85
3.95
12.1
33.25
PDE3,4inhibition+Isoproterenol 1µM
1.8
3.9
11.45
32.30
β1-ARs
Control
1.7
3.2
9.3
25.95
Isoproterenol 1 µM
1.7
3.85
11.1
30.15
PTX
1.7
3.2
9.35
25.95
PTX + Isoproterenol 1 µM
1.85
3.85
11.1
30.15
PDE3,4 inhibition
1.9
3.95
11.9
32.85
PDE3,4 inhibition + Isoproterenol 1 µM 1.8
3.9
11.5
31.65
β2-ARs
Control
1.6
3.1
8.55
24.05
Isoproterenol 1 µM
1.6
3.0
8.9
25.35
PTX
1.6
3.05
8.55
24.05
PTX + Isoproterenol 1 µM
1.6
3.05
10.1
29.4
PDE3,4 inhibition
1.6
3.1
9.9
29.65
PDE3,4 inhibition + Isoproterenol 1 µM 1.6
3.15
10.7
31.8
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Figure 3.10 Mouse action potential and underlying major ionic currents upon activation of β2-ARs with the
inhibition of Gi. Panel A: Simulated mouse action potentials for control (solid line) and upon activation of β2-ARs
alone (β1-ARs are blocked) with the inhibition of Gi (dashed line). Panel B: Simulated major ionic currents underlying
mouse action potential in control. Panel C: Simulated major ionic currents underlying mouse action potential after
the application of 1 μM isoproterenol and the inhibition of G i with PTX. In Panels A-C, action potentials and ionic
currents are shown after 300 s stimulation with 1 Hz.

APD50 change is less than 2%. However, prolongations of APD75 and APD90 are quite
significant, 18% and 22%, respectively, suggesting a strong effect of stimulation of β2-ARs (see
also Table 1). The effect of an application of 1 µM isoproterenol without PTX is significantly
smaller and increases APD75 and APD90 by ~5% only (Table 1). Even larger increases in APD75
and APD90 are observed upon application of 1 µM isoproterenol and inhibition of PDE3 and PDE4
(25% and 32%, respectively, Table 1). Thus, stimulation of β2-ARs with blocked β1-ARs can
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produce significant physiological effects on APDs upon stimulation with 1 µM isoproterenol and
additional inhibition of Gi or PDE3 and PDE4.
Our mathematical model allows for exposing the mechanisms of APD changes at different
levels of repolarization after stimulation of β2-ARs with 1 µM isoproterenol in the PTX-pretreated
myocytes. Figure 3.10B and C plot the behavior of the major repolarization currents at early phases
of repolarization (APD25 and APD50). The lack of changes in APD25 and APD50 are explained by
a relatively small increase in the inward currents INa and ICaL, which is balanced by a similarly
small increase in the outward current IKto,f. The changes in APD75 and APD90 are determined
predominantly by the changes in the inward current ICaL and the outward current IKur: ICaL increased
by ~1.8 pA/pF and IKur increased by only ~0.5 pA/pF, suggesting prolongation of APD75 and
APD90.
Figure 3.11 shows changes in the major ionic currents upon stimulation of both β1-ARs and
β2-ARs, β1-ARs alone, or β2-ARs alone. Stimulation of both β1-ARs and β2-ARs, or β1-ARs alone
demonstrate similar patterns of changes in ionic currents under different physiological conditions
(Fig. 3.11A and B). Without isoproterenol, an application of PTX does not affect current
magnitudes, while inhibition of PDE3 and PDE4 increases INa, ICaL (both caveolar, ICaLc, and
extracaveolar, ICaLe, fractions), and IKur, and decreases IKto,f, leading to APD prolongation in the
latter case. The application of 1 µM isoproterenol without other interventions and the application
of 1 µM isoproterenol with inhibition of Gi or PDE3 and PDE4 result in larger increases in INa,
ICaL, and IKur, and decreases IKto,f, which also promote APD prolongation at all repolarization
levels.
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Figure 3.11 Simulated magnitudes of major ionic currents in mouse ventricular myocytes upon
stimulation of β1-ARs and β2-ARs under different physiological conditions. Panel A: Activation of both
β1-ARs and β2-ARs. Panel B: Activation of β1-ARs alone. Panel C: Activation of β2-ARs alone. In Panels
A-C, simulated data are shown for control (control), upon application of 1 μM isoproterenol (Iso1), with
the inhibition of Gi (PTX), upon application of 1 μM isoproterenol with the inhibition of Gi (PTX + Iso1),
with inhibition of PDE3 and PDE4 (PDE3,4), and upon application of 1 μM isoproterenol with the
inhibition of PDE3 and PDE4 (PDE3,4 + Iso1); ionic currents are shown after 300 s stimulation with 1
Hz.

A different picture is observed during stimulation of β2-ARs alone (Fig. 3.11C). Without
isoproterenol, the application of PTX does not affect current magnitudes. Other interventions do
not affect APD25 and APD50 significantly as well (Table 1). The application of 1 µM isoproterenol
without other interventions increases mostly INa, ICaL, and IKto,f, which balance each other, resulting
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in relatively small changes in APD75 and APD90 (~5% increase of both). However, more significant
changes are observed in APD75 and APD90 (15% - 32% increase) upon stimulation of β2-ARs with
1 µM isoproterenol and inhibition of Gi and PDE3 and PDE4 (Table 1). While there is no
experimental data on the effects of stimulation of β2-ARs in wild type mouse ventricular myocytes,
the data on APD50 and APD90 in transgenic (TG) β2-AR overexpressing mouse ventricular
myocytes do not show significant change in APD50 compared to WT littermates, but APD90 is
significantly prolonged in TG mice63. In all cases, these prolongations are due to non-balanced
increase in ICaL and IKur, with the larger increase in the inward ICaL compared to the outward IKur
(Fig. 3.11C). In contrast to stimulation of both β1-ARs and β2-ARs, or β1-ARs alone, stimulation
of β2-ARs alone predominately increases the caveolar fraction of ICaL, ICaLc. The model predictions
on the changes in action potentials and underlying mechanisms can be verified by the future
experiments.

3.2.7 The effects on [Ca2+]i transients
Experimental data shows that stimulation of both β1-ARs and β2-ARs, β1-ARs alone, or β2ARs alone with isoproterenol enhances [Ca2+]i transients in mouse ventricular myocytes, however,
to different magnitudes. Micro molar concentrations of isoproterenol lead to a significant (up to 5fold) increase in intracellular [Ca2+]i transients obtained from mouse ventricular myocytes when
both β1-ARs and β2-ARs are intact64,65. Experimental stimulation of β2-ARs alone with 0.1 - 1.0
µM zinterol in PTX-pretreated ventricular myocytes increases [Ca2+]i transients to a lesser extent,
up to 2-fold66,67 (data on stimulation of β2-ARs alone with isoproterenol are not available). Our
simulations show similar behavior; however, we simulated stimulation with isoproterenol and a
corresponding block of β1-ARs or β2-ARs, because zinterol is not a specific agonist for β2-ARs
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and can affect both β1-ARs or β2-ARs, which create difficulties in the separation of the effects on
these receptors43.
Figure 3.12A demonstrates [Ca2+]i transients for control conditions and after application of 1
µM isoproterenol in the presence of Gi and β1-ARs block. It is seen that the peak value of [Ca2+]i
increases by about 1.4 fold, which is close to the experimental data66,67. Figure 3.12B demonstrates
simulations of the effects of both β1-ARs and β2-ARs, β1-ARs alone, and β2-ARs alone under
different physiological conditions and their comparisons with experimental data. Stimulation of
both β1-ARs and β2-ARs with 1 µM isoproterenol (no Gi inhibition) results in a 3.8-fold increase
in [Ca2+]i, which is in line with the experimental data64,65. The same result (3.8-fold increase in
[Ca2+]i) is obtained in the simulation of the stimulation of β1-ARs alone. However, stimulation of
β2-ARs alone with 1 µM isoproterenol without inhibition of Gi does not affect [Ca2+]i. Inhibition
of Gi by PTX does not change [Ca2+]i transients for all three patterns of β-ARs. However,
stimulation of both β1-ARs and β2-ARs with 1 µM isoproterenol plus PTX slightly increases [Ca2+]i
as compared with 1 µM isoproterenol alone (4.3-fold increase). Stimulation of β1-ARs alone
increases [Ca2+]i to the same degree as the stimulation of both β1-ARs and β2-ARs without
inhibition of Gi (3.8-fold increase). Stimulation of β2-ARs alone increases [Ca2+]i only by 1.4-fold
(Fig. 3.12B).
[Ca2+]i transients are also affected by the inhibition of PDE3 and PDE4. Our simulation data
shows an increase in [Ca2+]i upon inhibition of PDE3 and PDE4 without isoproterenol
application when both β1-ARs and β2-ARs are available, β2-ARs are blocked, or β1-ARs are
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blocked by 3.0-, 2.9-, or 1.7-folds, respectively. An additional application of 1 µM isoproterenol

leads to a
Figure 3.12 [Ca2+]i transients in mouse ventricular myocytes upon stimulation of β1-ARs and β2-ARs
under different physiological conditions. Panel A: Simulated [Ca2+]i transients obtained for control and
after application of 1 μM isoproterenol with the inhibition of Gi (PTX). Panel B: Experimental and
simulated data on a relative increase in [Ca2+]i transients. Experimental data by Despa et al.64 and Wang
et al.65 are obtained upon stimulation of both β1-ARs and β2-ARs; experimental data by Sabri et al.66 and
Xiao et al.67 are obtained upon stimulation of β2-ARs with zinterol (0.1 μM and 1.0 μM, respectively).
Simulations are performed for stimulation of both β1-ARs and β2-ARs, β1-ARs alone, and β2-ARs alone
under different physiological conditions: control (control), upon application of 1 μM isoproterenol (Iso),
upon the inhibition of Gi (PTX), upon application of 1 μM isoproterenol with the inhibition of Gi (PTX +
Iso), with the inhibition of PDE3 and PDE4 (PDE3,4), or upon application of 1 μM isoproterenol with
the inhibition of PDE3 and PDE4 (PDE3,4 + Iso). [Ca2+]i transients are shown after 300 s stimulation
with 1 Hz.
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larger increase in [Ca2+]i transients when both β1-ARs and β2-ARs are available, β2-ARs are
blocked, or β1-ARs are blocked, by 4.9-, 4.9-, or 2.0-folds, respectively (Fig. 3.12B).
Thus, stimulation of both β1-ARs and β2-ARs or β1-ARs alone results in strong increases in
[Ca2+]i transients, while the effects of stimulation of β2-ARs alone can be revealed only upon
stimulation with isoproterenol during inhibition of Gi or PDE3 and PDE4.

3.2.8 The effects on Ca2+ and Na+ fluxes
Our model allows for evaluation of various Ca2+ and Na+ integral fluxes and their modifications
by stimulations of β1-ARs and β2-ARs by isoproterenol under different experimental conditions
(Figs. 3.13-3.15), which can be verified by future experiments. The effects of β1-ARs were
investigated in detail in Ref. 27 and they are similar to the effects of β1-ARs and β2-ARs together
(compare Fig. 3.14A and Fig. 3.14B, Fig. 3.15A and Fig. 3.15B).
Stimulation of both β1-ARs and β2-ARs or β1-ARs alone with 1 µM isoproterenol results in
~1.5- to 2.0-fold increase in major integral Ca2+ fluxes (through the L-type Ca2+ channels, ICaL,
Ca2+ release influx, Jrel, Ca2+ uptake influx minus Ca2+ leak from the SR, Jup - Jleak, Ca2+ efflux
through the Na+/Ca2+ exchanger, JNaCa, and Ca2+ amount bound to troponin, Jtrpn). The effects of
stimulation of β2-ARs alone is smaller and can be only revealed with inhibition of Gi. Figure 3.13,
A and B, demonstrates the effects of stimulation of β2-ARs alone with 1 µM isoproterenol and
inhibition of Gi by PTX. It is seen that stimulation of β2-ARs leads to an increase in Ca2+ influx
through the L-type Ca2+ channels from 1.23 M to 1.67 M (36% increase) during cardiac cycles
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Figure 3.13 Integrated Ca2+ and Na+ fluxes (influxes). Simulation of the selective activation of β2-ARs with
1 µM isoproterenol (β1-ARs are blocked) and inhibition of Gi by PTX on the integrated Ca2+ and Na+ fluxes
(influxes) in isolated mouse ventricular myocyte model cell during one cardiac cycle. Simulated Ca2+
influxes are shown in Panels A and B. Simulated Na+ influxes are shown in Panels C and D. Simulations
for control conditions are shown in Panels A and C. Simulations for 1 µM isoproterenol and inhibition of
Gi by PTX are shown in Panels B and D. Ca2+ and Na+ fluxes are shown after 300 s of stimulation with 1
Hz.
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Figure 3.14 Magnitudes of the integral Ca2+ fluxes. Simulated magnitudes of the integral Ca2+ fluxes in
mouse ventricular myocytes upon stimulation of β1-ARs and β2-ARs under different physiological
conditions. Panel A: Activation of both β1-ARs and β2-ARs. Panel B: Activation of β1-ARs alone. Panel C:
Activation of β2-ARs alone. In Panels A-C, simulated data on Ca2+ release from the sarcoplasmic reticulum
(Jrel), Ca2+ influx through the L-type Ca2+ channels (JCaL), difference between Ca2+ uptake and Ca2+ leak
from the SR (Jup - Jleak), and Ca2+ flux through the Na+/Ca2+ exchanger (JNaCa) are shown for control
(control), upon application of 1 μM isoproterenol (Iso), with the inhibition of Gi (PTX), upon application
of 1 μM isoproterenol with the inhibition of Gi (PTX + Iso), with the inhibition of PDE3 and PDE4
(PDE3,4), or upon application of 1 μM isoproterenol with the inhibition of PDE3 and PDE4 (PDE3,4 +
Iso). Integral Ca2+ fluxes are shown after 300s stimulation with 1 Hz.

(1 Hz stimulation). Increases in Ca2+ influx results in an increase in Ca2+-induced Ca2+ release,
from 28 M to 37 M (30% increase; similar increase is observed for Jup - Jleak). An increase in
intracellular [Ca2+]i transients after an application of isoproterenol also increases Ca2+ extrusion
from the cytosol by the Na+/Ca2+ exchanger, JNaCa, from 2.78 M to 3.23 M (16% increase). The
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Ca2+ amount bound to troponin during one cardiac cycle (1000 ms, 1 Hz), which is important for
cardiac cell contraction, is also increased by ~33%, from 11.2 M to 14.9 M.
Stimulation of β2-ARs alone with 1 µM isoproterenol and inhibition of Gi by PTX also affects
the Na+ integral fluxes (Fig. 3.13, C and D). The Na+ influx by the fast Na+ current, JNa, increases
by 14%, from 3.89 µM to 4.44 µM. A little change is seen for the background Na + influx, JNab,
from 45.6 µM to 46.3 µM (1.5% increase); however, Na+ influx through the Na+/Ca2+ exchanger,
JNaCa, increases by 16%, from 8.3 µM to 9.7 µM, and Na+ extrusion by Na+-K+ pump, JNaK, is also
increased from 57.6 µM to 66.9 µM (16% increase).
Cumulative simulated data on the effects of both β1-ARs and β2-ARs, β1-ARs alone, or β2-ARs
alone on the Ca2+ and Na+ integral fluxes under different interventions are shown in Figs. 3.14 and
3.15. Figure 3.14 plots the data on Ca2+ fluxes. Stimulation of both β1-ARs and β2-ARs or β1-ARs
alone under different physiological conditions results in similar changes in Ca2+ fluxes.
Stimulation of both β1-ARs and β2-ARs with 1 µM isoproterenol increases JCaL from 1.6 µM to
3.3 µM (109% increase), Jrel from 35 µM to 61 µM (75% increase; similar increase is in Jup - Jleak),
and JNaCa from 3.1 µM to 4.7 µM (51% increase). Very similarly, stimulation of β1-ARs alone with
1 µM isoproterenol increases JCaL from 1.5 µM to 3.3 µM (112% increase), Jrel from 35 µM to 62
µM (75% increase; similar increase is in Jup - Jleak), and JNaCa from 3.1 µM to 4.6 µM (52%
increase). In contrast, stimulation of β2-ARs alone with 1 µM isoproterenol only slightly increases
Ca2+ influxes: JCaL from 1.2 µM to 1.4 µM (10% increase), Jrel from 28 µM to 30 µM (5% increase;
similar increase is in Jup - Jleak), and JNaCa from 2.8 µM to 2.9 µM (5% increase). Inhibition of Gi
with PTX does not change Ca2+ fluxes in all three cases. Gi inhibition only slightly changes the
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Figure 3.15 Magnitudes of integral Na+ fluxes. Simulated magnitudes of integral Na+ fluxes in mouse
ventricular myocytes upon stimulation of β1-ARs and β2-ARs under different physiological conditions.
Panel A: Activation of both β1-ARs and β2-ARs. Panel B: Activation of β1-ARs alone. Panel C: Activation
of β2-ARs alone. In Panels A-C, simulated data on Na+ influx through the fast Na+ channels (JNav),
background Na+ influx (JNab), Na+ flux through the Na+/Ca2+ exchanger (JNaCa), and Na+ flux through
the Na+-K+ pump (JNaK) are shown for control (control), upon application of 1 μM isoproterenol (Iso),
with the inhibition of Gi (PTX), upon application of 1 μM isoproterenol with the inhibition of Gi (PTX +
Iso), with the inhibition of PDE3 and PDE4 (PDE3,4), or upon application of 1 μM isoproterenol with the
inhibition of PDE3 and PDE4 (PDE3,4 + Iso). Integral Na+ fluxes are shown after 300 s stimulation with
1 Hz.

results of stimulation of both β1-ARs and β2-ARs with 1 µM isoproterenol: increases JCaL from 1.6
µM to 3.6 µM (128% increase), Jrel from 35 µM to 63 µM (80% increase), and JNaCa from 3.1 µM
to 4.9 µM (60% increase). Inhibition of Gi during stimulation of β1-ARs alone with 1 µM
isoproterenol produces the same effect as stimulation without inhibition of Gi. However,

68

stimulation of β2-ARs alone with 1 µM isoproterenol plus Gi inhibition dramatically changes the
results obtained without inhibition of Gi: it increases JCaL from 1.2 µM to 1.7 µM (36% increase),
Jrel from 28 µM to 37 µM (30% increase), and JNaCa from 2.8 µM to 3.2 µM (16% increase). These
data suggest that the effects of stimulation of β2-ARs alone on Ca2+ fluxes can be revealed upon
inhibition of Gi. Figure 3.14 also demonstrates the effects of inhibition of PDE3 and PDE4 without
and with stimulation by 1 µM isoproterenol. Quite a large effect on Ca2+ fluxes occurs upon
inhibition of PDE3 and PDE4, when both β1-ARs and β2-ARs are intact or β2-ARs are blocked,
which is similar to the effect of stimulation by 1 µM isoproterenol alone. More interesting are the
effects of PDE3 and PDE4 inhibition without and with 1 µM isoproterenol on Ca2+ integral fluxes
when β2-ARs are stimulated alone. In the case of PDE3 and PDE4 inhibition alone, JCaL increases
from 1.2 µM to 1.6 µM (33% increase), Jrel from 28 µM to 45 µM (61% increase), and JNaCa from
2.8 µM to 3.2 µM (14% increase). An additional application of 1 µM isoproterenol only slightly
increases Ca2+ fluxes: JCaL from 1.6 µM to 1.9 µM (14% increase), Jrel from 45 µM to 48 µM (6%
increase), and JNaCa from 3.2 µM to 3.4 µM (8% increase).
Figure 3.15 shows cumulative simulated data on the effects of both β1-ARs and β2-ARs, β1ARs alone, or β2-ARs alone on the Na+ integral fluxes under different interventions. As in the case
of Ca2+ fluxes, stimulation of both β1-ARs and β2-ARs or β1-ARs alone under different
physiological conditions results in similar changes in Na+ fluxes. Stimulation of both β1-ARs and
β2-ARs with 1 µM isoproterenol increases JNa from 3.9 µM to 4.2 µM (8% increase), JNab from
45.6 µM to 46.0 µM (1% increase), JNaCa from 9.3 µM to 14.0 µM (51% increase), and JNaK from
58.5 µM to 67.7 µM (16% increase). Similarly, stimulation of β1-ARs alone with 1 µM
isoproterenol increases JNa from 3.8 µM to 4.1 µM (9% increase), JNab from 45.4 µM to 45.8 µM
(1% increase), JNaCa from 9.2 µM to 13.9 µM (52% increase), and JNaK from 58.1 µM to 67.5 µM
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(16% increase). In contrast, stimulation of β2-ARs alone with 1 µM isoproterenol leads to
significantly smaller increases of Na+ influxes, except for JNa: JNa from 3.9 µM to 4.2 µM (9%
increase), JNab from 45.6 µM to 45.8 µM (0.5% increase), JNaCa from 8.3 µM to 8.8 µM (5%
increase), and JNaK from 57.6 µM to 60.4 µM (5% increase). Inhibition of Gi with PTX does not
change Na+ fluxes in all three cases. Stimulation of both β1-ARs and β2-ARs or β1-ARs alone with
1 µM isoproterenol plus inhibition of Gi show Na+ fluxes increase, which is similar to the effects
of 1 µM isoproterenol alone. However, stimulation of β2-ARs alone with 1 µM isoproterenol plus
Gi inhibition remarkably changes the results: JNa increases from 3.9 µM to 4.4 µM (14% increase),
JNab from 45.6 µM to 46.3 µM (1.6% increase), JNaCa from 8.3 µM to 9.7 µM (16% increase), and
JNaK from 57.6 µM to 66.9 µM (16% increase).
Thus, simulation data suggest that the effects of stimulation of β2-ARs alone on Na+ fluxes can
be more reliably revealed upon inhibition of Gi. Na+ fluxes upon inhibition of PDE3 and PDE4
without and with 1 µM isoproterenol do not differ significantly from those obtained upon
stimulation with the same amount of isoproterenol and inhibition of Gi for all three case of β1-ARs
and β2-ARs availability. In terms of revealing the effects of β2-ARs, the differences in changes of
Na+ fluxes upon inhibition of PDE3 and PDE4 without and with 1 µM isoproterenol are rather
small compared to the usage of inhibition of Gi.

3.2.9 The effects on the Na+-K+ pump and [Na+]i decline
The Na+-K+ pump, which is regulated by phospholemman, is one of the important players in
the sympathetic stimulation of cardiac cells64,68. Experimental data demonstrates that increased
activity in the Na+-K+ pump upon stimulation with isoproterenol results in [Na+]i decline in cardiac
cells68. Such a decline in [Na+]i was suggested to be a protective mechanism against cellular Ca2+

70

overload and pro-arrhythmic events. However, the contribution of different types of β-ARs to
[Na+]i decrease was not studied experimentally.
Therefore, we simulated the effects of the stimulation of β1-ARs and β2-ARs on the dynamics of
intracellular [Na+]i concentration under different physiological conditions (Fig. 3.16). When both
β1-ARs and β2-ARs are intact, stimulation of the cell with 1 μM isoproterenol leads to a reduction
of [Na+]i to a new steady-state value within ~600 seconds (black solid line in Fig. 3.16). Additional
inhibition of Gi with PTX results in a significantly faster decline in [Na+]i (red solid line in Fig.
3.16). To reveal the major contributors to the decline in [Na+]i, we performed simulations when

Figure 3.16 [Na+]i concentration as function of time. Simulated [Na+] i concentration as function of time
in mouse ventricular myocytes upon stimulation of β1-ARs and β2-ARs under different physiological
conditions. Data are shown for control (Control), upon application of 1 μM isoproterenol (1 μM Iso),
with the inhibition of Gi (PTX), and upon application of 1 μM isoproterenol with the inhibition of Gi (PTX
+ Iso). Dashed lines plot steady state [Na+ ]i concentrations in the cell in control and during inhibition of
Gi; solid lines plot [Na+ ]i concentrations after application of 1 μM isoproterenol. Simulations were
performed for the case, when both β1-ARs and β2-ARs are intact (black lines for control and red lined for
the inhibition of Gi), when β2-ARs are inhibited (green lines, data with and without inhibition of Gi are
identical), and when β1-ARs are inhibited (blue lines for control and dark red lined for the inhibition of
Gi).
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only one type of β-ARs was present. In the case when β2-ARs are blocked, an application of 1 μM
isoproterenol results in a [Na+]i decline (green solid line in Fig. 3.16), the rate of which is similar
to the case when both β1-ARs and β2-ARs are intact without inhibition of Gi. Additional Gi
inhibition does not affect the simulation results (data not shown). In the case when β1-ARs were
blocked, an application of 1 μM isoproterenol results in a relatively slow [Na+]i decline (blue solid
line in Fig. 3.16). Additional inhibition of Gi with PTX dramatically accelerates the isoproterenolinduced [Na+]i decline (dark red line in Fig. 3.16), with a rate similar to the case of inhibition of
Gi when β1-ARs and β2-ARs are intact (red solid line in Fig. 3.16). Thus, our simulations suggest
an important role of the stimulation of β2-ARs in [Na+]i removal in the presence of PTX (inhibition
of Gi). This interesting simulation result is supported by the experimental observations of the
stronger coupling of β2-ARs to Gs protein than of β1-ARs69, the primary localization of β2-ARs in
the caveolar compartment20,31, and that most of INaK activity is localized in the caveolar
compartment70. However, direct experimental observation of the important role of β2-ARs in this
case is currently absent and can be verified by future experiments.

3.2.10 The contribution of phosphorylation of PKA targets to the changes in the action
potential and [Ca2+]i transients
Phosphorylation of the proteins involved in intracellular signaling systems plays an important
role in healthy and diseased hearts. Stimulation of the β1- and β2-adrenergic signaling systems
results in the phosphorylation of several PKA target proteins that affect action potential and [Ca2+]i
transients. Therefore, it is of significant interest to reveal the major PKA targets that contribute to
the changes in the action potential and [Ca2+]i transients upon stimulation. The experimental
investigation of individually eliminating PKA target protein phosphorylation is quite challenging
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whether using biochemical methods, due to the complex effects of the interventions (e.g.,
activation of phosphatases), or molecular biology methods, due to the difficulties in the generation
of transgenic mice with mutations of the phosphorylation sites of the target proteins.
We used our mathematical model to simulate the effects of elimination of protein
phosphorylation on the changes in the action potential and [Ca2+]i transient upon stimulation of
mouse ventricular myocytes with 1 μM isoproterenol for the two most interesting cases: 1) both
β1- and β2-ARs are intact; 2) β1-ARs are blocked and Gi is inhibited. We performed simulations
for control conditions without application of isoproterenol, for control conditions with application
of 1 μM isoproterenol, and for the conditions with application of 1 μM isoproterenol when the
phosphorylation of phospholamban, troponin I, phospholemman (regulates Na+-K+ pump),
ryanodine receptors, the L-type Ca2+ channels, or the channels responsible for the transient
outward K+ current IKto,f and the ultrarapidly activating K+ current IKur is removed. To eliminate
phosphorylation, the rate of phosphorylation of the particular protein investigated was decreased
by factor of 1000 and the dissociation constant for phosphorylation was increased by 1000. The
model was then run for 10,000 seconds to ensure equilibrium. As a result, protein phosphorylation
levels became negligible. Finally, starting from these initial conditions, 1 μM isoproterenol was
applied for 300 seconds to the electrically stimulated cell (Istim = 80 pA/pF, τstim = 1.0 ms), and the
action potential and [Ca2+]i transient during the 300th period was analyzed. The changes in the
shape of the action potential and [Ca2+]i transient are shown in Fig. 3.17, and the changes in
quantitative measures (APD50, APD90, and [Ca2+]i transient magnitude) are shown in Fig. 3.18.
When both β1- and β2-ARs are intact, the most notable changes in the action potential shape
are seen upon phosphorylation removal in proteins encoding ionic currents ICaL, IKto,f, and IKur (Fig.
3.17A). These changes are also evident in Fig. 3.18, A and B, for APD50 and APD90, except for
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IKto,f, which phosphorylation removal does not affect APD90. The removal phosphorylation of the
L-type Ca2+ channels significantly shortened APD50 from 3.8 ms (control with 1 μM isoproterenol)
to 3.1 ms and APD90 from 30.0 ms to 14.7 ms. The removal of phosphorylation of the channels
responsible for the ultrarapidly activating K+ current IKur significantly prolonged APD50 from 3.8
ms to 4.8 ms and APD90 from 30.0 ms to 42.4 ms. The removal of phosphorylation of the channels

Figure 3.17 Simulated action potentials and [Ca2+]i transients. Simulated action potentials (Panels A and
C) and [Ca2+]i transients (Panels B and D) obtained upon stimulation of both β1-ARs and β2-ARs without
inhibition of Gi (Panels A and B) and β2-ARs with inhibition of Gi by PTX (Panels C and D). Data are
shown for control without isoproterenol (black lines), control with 1 μM isoproterenol (red lines), and upon
stimulation with 1 μM isoproterenol and removal of phosphorylation of phospholamban (green lines),
troponin I (blue lines), phospholemman (which regulates Na+-K+ pump, magenta lines), the L-type Ca2+
channels (cyan lines), the channels responsible for IKto,f (gray lines), the channels responsible for IKur (dark
red lines), and ryanodine receptors (dark green lines). The action potential and [Ca 2+] i transients are
shown during the 300th stimulation period with 1 Hz.
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responsible for the transient outward K+ current IKto,f significantly shortened only APD50 from 3.8
ms to 3.2 ms. When only β2-ARs were selectively stimulated with 1 μM isoproterenol along with
Gi inhibition (β1-ARs are blocked), significant shortening of APD90 from 29.4 ms (control with 1
μM isoproterenol) to 22.7 ms is obtained only upon removal of phosphorylation in the L-type Ca2+
channels (Fig. 3.17C and Fig. 3.18, A and B).
The picture of the contribution of the phosphorylation of different PKA targets on [Ca2+]i
transient is more complex. When both β1- and β2-ARs are intact, the most notable changes in the
magnitude of isoproterenol-stimulated [Ca2+]i transient is seen upon phosphorylation removal of
proteins encoding ICaL (Fig. 3.17B and Fig. 3.18C). Phosphorylation removal of phospholamban,
ryanodine receptors, and the channels responsible for the transient outward K+ current, IKto,f, tend
to reduce and phosphorylation removal of phospholemman, troponin I, and the channels
responsible for the ultrarapidly activating K+ current IKur tend to increase isoproterenol-stimulated
[Ca2+]i transient. We suggest that the availability of multiple regulation factors for [Ca2+]i transient
upon stimulation of the β-adrenergic signaling system ensures reliable control of Ca2+ dynamics
under different physiological conditions. When only β2-ARs were selectively stimulated with 1
μM isoproterenol along with Gi inhibition (β1-ARs are blocked), the largest effect (decrease) on
[Ca2+]i transient is obtained upon phosphorylation removal in the L-type Ca2+ channels (Fig. 3.17D
and Fig. 3.18C). Phosphorylation removal in only two other proteins affected [Ca2+]i transient:
phospholemman and phospholamban. Phosphorylation removal in phospholemman increased
[Ca2+]i transient and phosphorylation removal in phospholamban decreased [Ca2+]i transient as
compared to the isoproterenol-stimulated [Ca2+]i under control (Fig. 18D).
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Figure 3.18 Changes in APD50, APD90, and [Ca2+]i transient magnitudes. Simulated changes in APD50
(Panel A), APD90 (Panel B), and [Ca2+]i transient magnitudes (Panel C) obtained upon stimulation of both
β1-ARs and β2-ARs without inhibition of Gi (black bars) and β2-ARs with inhibition of Gi by PTX (gray
bars). Data are shown for control without isoproterenol (c -Iso), control with 1 μM isoproterenol (c), and
upon stimulation with 1 μM isoproterenol and removal of phosphorylation of phospholamban (PLB),
troponin I (tni), phospholemman (PLM), the L-type Ca2+ channels (Ical), the channels responsible for IKto,f
(Ikto), the channels responsible for IKur (Ikur), and ryanodine receptors (ryr). The characteristics of the
action potential and [Ca2+]i transients are calculated during the 300th stimulation period with 1 Hz. Panel
D shows the experimental [Ca2+]i transients (gray bars with errors) in isoproterenol-stimulated mouse
ventricular myocytes from phospholamban-knockout mice with reintroduced wild type phospholamban
(KO-WT) and phospholamban with S16A mutation (KO-S16A). Experimental data were obtained by Chu
et al.71. Corresponding simulated data are obtained for [Ca2+]i transients in control and upon removal of
phospholamban phosphorylation, both stimulated with 1 μM isoproterenol (black bars). Data are shown in
% to the control (wild type) case.

While most of these simulations with phosphorylation removal of PKA target proteins require
verification by future experiments, we found one experiment that confirms our simulations. Chu
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et al.71 investigated the effects of phospholamban PKA phosphorylation site S16 on [Ca2+]i
transient in mouse ventricular myocytes. They reintroduced both wild type PLB and PLB with
S16A mutation into PLB-knockout mouse hearts and measured [Ca2+]i transients in corresponding
ventricular myocytes. The measurements have shown a significant decrease in [Ca2+]i transient in
myocytes with mutant PLB compared to those with wild type PLB (gray bars with errors in Fig.
3.18D)71. Our model demonstrated a similar decrease in [Ca2+]i transient upon removal PLB
phosphorylation (black bars in Fig. 3.18D).
Thus, our mathematical model is capable of revealing the major factors affecting the action
potential and [Ca2+]i transient upon stimulation of β1- and β2-ARs through phosphorylation of
specific PKA target proteins. The simulations suggest an alternative to the ion channel blockers
method of regulation of the action potential and [Ca2+]i transient upon selective actions on the
phosphorylation sites of the proteins involved in the β1- and β2-adrenergic signaling systems.

3.3

Sensitivity analysis
To estimate the mathematical model’s stability and major contributing factors to the changes

in the action potential and [Ca2+]i transient, we performed a sensitivity analysis. In the previous
paper30, where the mathematical model included only the β1-adrenergic signaling system, a
sensitivity analysis was carried out with respect to the major repolarization currents. With the
model presented in this chapter, we obtained very similar results. In addition, we performed a
sensitivity analysis with respect to the concentrations of major signaling proteins included in the
model of the combined β1- and β2-adrenergic signaling system. As the interbeat changes in the
concentrations of signaling proteins did not produce measurable effects on the action potential and
[Ca2+]i transient, we explored a method of analysis different from30. We ran the model cell for 300
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s for the control set of the model parameters and for the case, when one protein concentration
increased by 5%. Then the differences between APD25, APD50, APD75, APD90, action potential
amplitudes, and magnitudes of [Ca2+]i transients were calculated during the 300th period. The
results are shown in Fig. 3.19. It is seen that the largest contribution to APDs and [Ca2+]i transients
come from the total concentrations of β2-ARs, adenylyl cyclases, and phosphodiesterase of type 4.
In addition, the total concentration of PDE3 is one of the major contributing factors to the action
potential amplitude.

Figure 3.19 Absolute changes in APD25, APD50, APD75, APD90, action potential amplitudes, and
magnitudes of [Ca2+]i transients. Simulated absolute changes of action potential durations at 25% (Panel
A), 50% (Panel B), 75% (Panel C), and 90% repolarization (Panel D), action potential amplitude (Panel
E), and [Ca2+]i transient (Panel F) after 5% increase in concentrations of the major signaling proteins in
the combined β1-and β2-adrenergic signaling system. A 5% increase in concentrations of the major proteins
were set at time t = 0, and changes in action potential characteristics and [Ca 2+]i transient compared to
those at original protein concentrations are measured after 300-second stimulation at 1 Hz. Notations are
for control (C) and the changes of concentrations of β1-ARs (RB1), β2-ARs (RB2), stimulatory G protein
(Gs), inhibitory G protein (Gi), adenylyl cyclases, total (AC), phosphodiesterase of type 2 (PDE2),
phosphodiesterase of type 3 (PDE3), phosphodiesterase of type 4 (PDE4), and protein kinase A (PKA).
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We also performed a sensitivity analysis with respect to the changes in the initial conditions.
For this purpose, we run the model for 300 s with the steady-state initial conditions and the model
with increased values of all initial conditions by 5%. In this case, the differences in the
transmembrane voltage and [Ca2+]i concentration at the end of the 300-second simulations were
only 1.66% and 0.92%, respectively.

3.4

Discussion
Thus, in the previous chapters of this dissertation, a new compartmentalized model for the

combined 1- and 2-adrenergic signaling system in mouse ventricular myocytes is developed. The
model is an extension of the previously published model of the 1-adrenergic signaling system27,
which includes compartmentalization and the effects on the action potential, ionic currents, and
Ca2+ and Na+ dynamics. The new model was explored to investigate the contribution of each
receptor type (1-ARs and 2-ARs) to the regulation of electrical activity and ionic homeostasis in
cardiac cells upon stimulation with isoproterenol under several physiological conditions which are
commonly used in experiments. We found that the major inotropic, lusitropic, and chronotropic
effects are due to the activation of 1-ARs. The 2-ARs are silent under control conditions or upon
inhibition of Gi, and cause tiny effects upon stimulation with nearly saturating concentrations of
isoproterenol. The effects of 2-ARs can be revealed upon application of isoproterenol in PTXpretreated mouse ventricular myocytes or in the cells with inhibited PDE3 and PDE4. The model
allows for determination of the mechanisms of action potential prolongation and increase in [Ca2+]i
transients upon stimulation of β1-ARs and/or β2-ARs. The model also made testable predictions
on the changes of Ca2+ and Na+ fluxes, [Na+]i decline, and the contribution of phosphorylation of
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different PKA targets to the changes in action potential and [Ca2+]i transients during stimulation
of β1-ARs and/or β2-ARs.

3.4.1 Differential effects of the β1- and β2-adrenergic signaling systems in the heart
β1- and β2-adrenergic receptors have different physiological roles in regulation of the action
potential, ionic currents, and Ca2+ and Na+ dynamics in cardiac myocytes. Stimulation of β1-ARs
activates Gs-mediated signaling pathway, which is characterized by a relatively large production
of the major signaling molecule, cAMP. β2-ARs, in contrast, activates both Gs- and Gi-mediated
signaling systems, resulting in less pronounced effects42. In addition, β1- and β2-adrenergic
receptors have different cellular localization. Experimental data shows that β1-adrenergic receptors
are mostly distributed outside of the caveolar compartment, while β2-adrenergic receptors are
predominantly localized in the caveolar compartment20,31. In accordance with the experimental
findings, our model includes only 1% of β1-adrenergic receptors in the caveolar compartment, with
the majority of them distributed between the extracaveolar and cytosolic compartments. In
contrast, 99% of β2-adrenergic receptors in the model are localized in the caveolar
compartment20,34. Differential localization and coupling to Gs and Gi proteins results in different
functional consequences: selective activation of β1-adrenergic receptors in mouse ventricular
myocytes under control conditions both in experiments and in our simulations leads to a significant
increase in [Ca2+]i transient and myocyte contraction, while selective activation of β2-adrenergic
receptors does not have any effect on myocyte contractility67. Stimulation of β1-adrenergic
receptors also leads to phosphorylation of phospholamban, while stimulation of β2-adrenergic
receptors does not produce this effect under control conditions72.
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While, in general, the physiological effects of β1-ARs are stronger than those of β2-ARs, they
are different in different species. In some cases, the effects of β2-ARs are not seen at all under
normal physiological conditions, which produces discussion about their physiological importance
for cardiac function42,44. For example, in human ventricular myocytes, coupling of β2-ARs to the
changes in cardiac function (systolic tension response) was observed upon application of β 2-ARs
agonist zinterol73. In contrast, application neither β2-ARs agonist zinterol nor isoproterenol with
β1-ARs block elicited functional response in mouse ventricular myocytes, in particular, to the
effects on the L-type Ca2+ current41,43. In addition, experiments on stimulation of β2-ARs with
isoproterenol in β1-AR knockout mice did not produce a significant effect on phospholamban
phosphorylation60. Similar data are obtained for rat ventricular myocytes, where activation of β 2ARs caused an increase in cAMP production, but did not affect Ca2+ dynamics, cardiac contraction,
and phospholamban phosphorylation74. On the other hand, experimental data shows that the
stimulation of β2-ARs in canine ventricular myocytes enhanced the L-type Ca2+ current and
myocyte contraction, but did not affect phospholamban phosphorylation40.
Such different experimental results on the physiological effects of β2-ARs in cardiac cells are
due not only to species differences, but also due to the usage of zinterol as a specific agonist of β2ARs beyond its specificity concentrations. Experimental data shows that zinterol affinity for β2ARs and β1-ARs is ~40 nM and ~1 ‒ 3 µM, respectively45,46. It means that the effects of 1 µM
zinterol are non-specific for β2-ARs and can activate significant portion of β1-ARs. This issue was
studied in detail by Heubach et al.47, who has shown that 1 µM zinterol causes an increase in the
L-type Ca2+ current, but this effect is suppressed by 300 nM CGP 20712A, a selective β1-AR
antagonist. Therefore, throughout this study, we used isoproterenol as a β1-AR and β2-AR agonist,
but its action was simulated in the presence of selective antagonists, CGP 20712A for β1-ARs and
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ICI 118551 for β2-ARs. As result, we obtained non-contradictory simulation data, which explained
most of the experimental data obtained under similar physiological conditions. In particular, we
have shown that the physiological effects of inhibition of Gi by PTX or stimulation of β2-ARs with
1 µM isoproterenol without PTX are virtually absent. The effects of stimulation of β2-ARs with 1
µM isoproterenol can be revealed only with the additional inhibition of Gi by PTX or inhibition of
PDE3 and PDE4 by cilostamide and rolipram, respectively. Specifically, such effects of β 2-ARs
are obtained for the L-type Ca2+ current, [Ca2+]i transients, and phosphorylation of phospholamban,
which is similar to the experimental findings.

3.4.2 The effects of the β1- and β2-adrenergic signaling system on action potential and Ca2+
and Na+ dynamics
Our simulation data suggest differential effects of β1-ARs and β2-ARs on the mouse action
potential. Selective stimulation of β1-ARs or both β1-ARs and β2-ARs prolongs APDs at all levels
of repolarization, 25%, 50%, 75%, and 90%. This prolongation moderate and is similar to the
experimental observations and simulations obtained before27. However, simulation of the selective
activation of β2-ARs shows the effects mostly on APD75 and APD90 in mouse ventricular myocytes
only when Gi is blocked. The simulations also reveal major players in the prolongation of APDs
at 75% and 90% repolarization: the L-type Ca2+ current, ICaL, and the ultrarapidly activating K+
current, IKur. A significant portion of ICaL is localized in the caveolar compartment, which is mostly
affected by β2-ARs, and mainly diffusive fluxes of cAMP affects PKA and IKur in the extracaveolar
compartment, where only 1% of β2-ARs are located, leading to a significantly larger increase in
the inward ICaL as compared to the outward IKur. There is no experimental data on the effects of β2ARs on the wild type mouse action potential, and the experimental verification of these simulation
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predictions will be of great interest. However, an increase in APD90 and no change in APD50 in
mouse ventricular myocytes overexpressing β2-ARs compared to wild type littermates63 favors our
modeling predictions.
As found experimentally, activation of the β1- and β2-adrenergic signaling systems
significantly increases the magnitude of intracellular [Ca2+]i transients, however, to different
extents and depending on species and the concentration of agonist64,65,66,67,75,76. The effects of
stimulation of both β1-ARs and β2-ARs or β1-ARs alone is more pronounced than that for β2-ARs
alone, in particular in rodent ventricular cells where the increase can reach up to 5 times 64,65. In
larger species, such as rabbits and dogs, the increase is only by a factor of 275,76. Stimulation of β2ARs alone with application of PTX results in a relatively moderate increase in [Ca2+]i transients,
from 40% to 150% in rodents66,67,77 and up to 40% increase in dogs78. No significant increase in
[Ca2+]i transients without PTX are observed in rats77 and in rabbits79. Our simulations with mouse
ventricular myocytes show similar results. Stimulation of both β1-ARs and β2-ARs or β1-ARs alone
with 1 µM isoproterenol results in a 3.8-fold increase in [Ca2+]i transients, but stimulation of β2ARs alone with the same concentration of isoproterenol does not produce any effect (Fig. 3.12).
Inhibition of Gi (effects of PTX) does not alter the effects of both β1-ARs and β2-ARs or β1-ARs
alone, but it uncovers the effects of stimulation of β2-ARs alone, where a 39% increase in [Ca2+]i
transient is obtained (Fig. 3.12).
The simulations also demonstrate differences in integral Ca2+ and Na+ fluxes upon stimulation
of both β1-ARs and β2-ARs, β1-ARs alone, or β2-ARs alone. The integral Ca2+ fluxes increase to
much larger values, when both β1-ARs and β2-ARs or β1-ARs alone are activated than when β2ARs alone are activated (Fig. 3.14). What is remarkable is that the relative percentage contribution
of each Ca2+ influx mechanism does not change too much upon different physiological conditions,
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shown in Fig. 3.14. For example, 4%-5% of the total Ca2+ entry into cytosol is due to the L-type
Ca2+ channels, which triggers Ca2+-induced Ca2+ release from the SR (91%-93% of the total Ca2+
entry into cytosol); 7%-8% of Ca2+ entry is extruded by the Na+/Ca2+ exchanger; and ~0.5% Ca2+
is extruded by the sarcolemmal Ca2+ pump. The differences in integral Na+ fluxes increases
between stimulations of both β1-ARs and β2-ARs or β1-ARs alone, on the one hand, and β2-ARs
alone, on the other hand, are less pronounced (Fig. 3.15). About 7% of Na+ enters the cell through
the fast Na+ channels, ~16% enters through the Na+/Ca2+ exchanger, and ~77% enters through
different background mechanisms (large transmembrane Na+ gradient, the Na+/H+ exchanger, the
Na+/HCO−3 co-transporter, etc.64). These influxes are counterbalanced by Na+ extrusion by the
Na+-K+ pump. The fractions differ from those evaluated for rabbits64, where about 22% of Na+
enter the cell through the fast Na+ channels, 60% through the Na+/Ca2+ exchanger, and 18%
through the background mechanisms, suggesting the Na+/Ca2+ exchanger to be the major player in
the Na+ transport into the cell. Further experiments are necessary to verify the predicted Na+ fluxes
in mouse ventricular cells.

3.4.3 The role of signaling proteins phosphorylation in the healthy and diseased cardiac
cells
Phosphorylation of signaling proteins is one of the major mechanisms of biochemical signal
transduction in cardiac cells. Upon stimulation or inhibition of the β1- and β2-adrenergic signaling
system, phosphorylation regulates ionic currents, pumps, transporters, as well as other intracellular
proteins involved in Ca2+ and Na+ dynamics and cellular contraction80,81. In healthy hearts,
activation of the β-adrenergic signaling system is a natural response to the increased heart load
during exercises, which leads to increased phosphorylation of PKA target proteins and ultimately
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to the changes in the action potential and Ca2+ dynamics. Diseased states, such as heart failure, are
accompanied by significant modifications of the β-adrenergic signaling: decreased expression of
the β1-adrenergic receptors, increased activity of Gi proteins, increased phosphorylation of the Ltype Ca2+ channels and ryanodine receptors, decreased phosphorylation of phospholamban82,83,84.
Therefore, the pharmacological effects on the β-adrenergic signaling system or its components are
among those methods for the treatment of heart failure83.
To better understand mechanisms of adaptive changes in the β-adrenergic signaling system in
human heart failure, mouse models of heart diseases were developed that recapitulate those found
in human subjects85,86. In particular, several strategies were developed to improve cardiac function
by affecting the β1- and β2-adrenergic signaling and its components in mice. Inhibition of cardiac
β-adrenergic receptor kinase 1 (βARK1, currently named GRK2), the cause of desensitization of
the β-adrenergic receptors in the failing hearts, significantly prolonged survival and β blocker
therapy in mice with severe heart failure87. Deletion of the phospholamban gene dramatically
enhanced survival of transgenic mice overexpressing β1-adrenoceptors88. Transgenic mice with
knock-in non-phosphorylated ryanodine receptors (S2808A mutant) were able to protect rolipramtreated mice from arrhythmias89.
Our simulations of selective removal of phosphorylation of PKA targets demonstrated
remarkable changes in the action potential duration due to dephosphorylation of the L-type Ca2+
channels and the channels responsible for IKur resulting both in increase and decrease of the action
potential duration (Figs. 3.17 and 3.18). These ion channels can be potential new targets for the
regulation of the electrical activity in the heart through modification of their phosphorylation. We
also found that [Ca2+]i transients are significantly modified by all investigated PKA targets in

85

mouse ventricular myocytes that provides a flexibility in the choice of potential drug targets or
genetic modifications of phosphorylation sites (Figs. 3.17 and 3.18).

3.4.4 Model limitations
While the developed model of the combined β1- and β2-adrenergic signaling system was
extensively verified by experimental data and simulated numerous experimental effects of
stimulation of β1-ARs and β2-ARs under different physiological conditions, it has some limitations.
One of the limitations comes from the low accuracy of biochemical and physiological experiments,
which can vary by multiple folds, up to an order of magnitude. The second is that not all model
parameters were measured directly in the experiments, and were adjusted numerically to fit the
experimental data. These adjustable parameters are: 1) background currents, which were adjusted
in the previous model27; 2) activation rates for Gs and Gi proteins, which are not directly measured
or measured with low accuracy, but adjusted to fit the experimental data on kinetics of
phosphorylation and dephosphorylation of the key signaling proteins, as well as the magnitude and
kinetics of cAMP and protein kinase A under different physiological conditions; 3) basal adenylyl
cyclase activities, which are responsible for background cAMP concentration without
interventions. The third limitation is the possible effects of the CaMKII-mediated signaling
system, which are not taken into account in the present model. However, the model of the
combined β1- and β2-adrenergic signaling system describes quite well significant portions of the
available experimental data obtained for mouse ventricular myocytes. In particular, it gives a noncontradictory description of the physiological effects of β2-ARs in wild type mice. The authors
consider this model as an intermediate step in the development of a more comprehensive
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mathematical model of the mouse ventricular myocytes, which will include multiple signaling
systems.

3.5

Conclusions
We developed a comprehensive experimentally-based compartmentalized mathematical model

of the combined β1- and β2-adrenergic signaling system in mouse ventricular myocytes. The model
describes the dynamics of major signaling molecules in different subcellular compartments;
kinetics and magnitudes of phosphorylation of ion channels, transporters, and Ca2+ handling
proteins; modifications of action potential shape and duration; and [Ca2+]i and [Na+]i dynamics
upon simultaneous stimulation of β1- and β2-adrenergic receptors, or during separate stimulation
of β1- or β2-ARs. The simulation results are compared to the experimental data obtained upon
stimulation of the β1- and β2-adrenergic signaling systems in mouse ventricular myocytes.
Simulations demonstrate that the separate stimulation of the β2-ARs under normal physiological
conditions does not affect action potential and [Ca2+]i transients, which is also observed in
experiments. The physiological effects of β2-ARs are revealed in simulations upon the inhibition
of Gi proteins or PDE3 and PDE4. The model also made testable predictions of the changes of the
action potential, magnitudes of [Ca2+]i and [Na+]i fluxes, the rate of decay of [Na+]i concentration
upon both combined and separate stimulation of β1- and β2-ARs, and the contribution of
phosphorylation of different PKA targets to the changes in the action potential and [Ca2+]i
transient.
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4

MATHEMATICAL MODELING PHYSIOLOGICAL EFFECTS OF THE
OVEREXPRESSION OF 2-ADRENOCEPTORS IN MOUSE VENTRICULAR
MYOCYTES

4.1

Introduction
Mice are important animals for studies of human disease. Multiple transgenic (TG) mice were

generated during the last decades for this purpose. These include overexpressions, knock-outs,
knock-ins, and genetic modifications of ion channels, transporters, and signaling proteins in mouse
hearts, brains, and other organs90. Such modifications have allowed for revealing major
mechanisms of generation of specific disease states in mice, with subsequent translation to human
subjects90.
Specifically, transgenic mice were generated with modifications of the β1- and β2-adrenergic
signaling systems and their components, to demonstrate their different roles in the heart.
Experimental investigations by Engelhardt et al.28 have shown that heart-specific overexpression
of β1-adrenoceptors leads to a progression of hypertrophy and heart failure. In this study, the
overexpression level of β1-adrenoceptors of TG mice was only 15 times the normal expression of
wild type (WT) mice. Such an overexpression resulted in progressive development of cardiac
hypertrophy, clinical signs of heart failure and premature deaths before the age of 14 months. On
the other hand, a study by Milano et al.29 demonstrated that cardiac-specific overexpression of β2adrenoceptors (195 fold) resulted in improved cardiac function. This resulted in increased basal
adenylyl cyclase activity, enhanced atrial contractility, and increased ventricular function in vivo.
More detailed studies of different levels of overexpression of β2-adrenoceptors (60-, 100-, 150-,
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and 350-fold) conducted by Liggett et al.91 concluded that cardiac function was dependent on the
level of overexpression. Their data have shown that mouse hearts tolerated enhanced cardiac
function without detriment for a period of more than 1 year only for 60-fold overexpression of β2adrenoceptors; other levels of overexpression resulted in cardiomyopathy.
Experimental data demonstrates interesting and intriguing differences in the response of the
WT mouse ventricular myocytes and ventricular myocytes from TG mice overexpressing β 2adrenergic receptors to β-adrenergic stimulation. WT mice show a large response to stimulation
with β1- and β2-adrenoceptor agonist isoproterenol42. Blocking β1-adrenoceptors (β1-ARs) in WT
mice basically eliminate this response, demonstrating that the role of β2-adrenoceptors (β2-ARs) is
minimal. Indeed, the response of WT mouse cardiac cells to stimulation of β2-adrenoceptors is
absent under normal physiological conditions and can be only revealed after application of
pertussis toxin (PTX, Gi inhibitor) or after inhibition of phosphodiesterases of type 3 and 4 (PDE3
and PDE4)41,42. On the other hand, ventricular myocytes from TG mice overexpressing β2-ARs do
not show notable responses to stimulation with β1-AR agonist norepinephrine without and with
application of PTX, and to stimulation with β2-AR agonist zinterol without application of PTX.
However, myocytes from TG mice demonstrate quite a significant response to stimulation with β2AR agonist zinterol in the presence of PTX67. In addition, this response can be inhibited by specific
β2-AR inhibitor ICI 118,55167.
Our model for the combined β1- and β2-adrenergic signaling system in mouse ventricular
myocytes was able to explain only experimental data on WT mice92. It showed the primary role of
β1-ARs in inotropic response to stimulation with β1- and β2-adrenoceptor agonist isoproterenol.
The model also demonstrated that the response to β2-AR stimulation was only notable with the
application of PTX or upon inhibition of PDE3 and PDE492. However, it is interesting whether our
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model can simulate the experimental data obtained from TG mice overexpressing β2-adrenoceptors
after modifications and can the model reveal different responses of WT and TG mice to βadrenergic stimulation.
Therefore, we developed and explored a compartmentalized mathematical model of ventricular
myocytes from TG mice overexpressing β2-adrenoceptors. The model is based on the previously
developed mathematical model of the combined β1- and β2-adrenergic signaling system in mouse
ventricular cells, which was extensively verified by experimental data92. In the new model, we
implemented differences in the model parameters between WT mice and TG mice overexpressing
β2-adrenoceptors and simulated different myocyte behavior found experimentally. We have shown
that β2-AR overexpression does not significantly affect action potential shape and duration, but the
effect is most notable upon stimulation of β2-ARs with zinterol in the presence of PTX. Significant
effects of zinterol on the L-type Ca2+ current in TG mice were also achieved with the model by
stimulation with zinterol plus PTX. We also found that [Ca2+]i transients are larger in TG mice as
compared to WT mice without any stimulation, and a significant increase in [Ca2+]i transients was
observed upon stimulation with zinterol after the application of PTX. Mechanisms of the changes
are disclosed by the simulations and the model limitations are discussed.
4.2

Methods

4.2.1 Model development
A mathematical model for TG mouse ventricular myocytes overexpressing 2-ARs is obtained
from our previously published model of the combined 1- and 2-adrenergic signaling system92.
We incorporated the following changes of the model parameters that correspond to the differences
between WT and TG mice found experimentally (shown in green in Fig. 4.1 and in Table 2).
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In TG mice overexpressing 2-ARs, we increased the concentration of 2-ARs by 200 fold
according to the experimental data by Milano et al.29. In addition, we reduced the concentration of
1-ARs by a factor of 0.0001, as these receptors are in inactive states and do not respond to
epinephrine and zinterol67,93. We also increased the expression of inhibitory G protein Gi in TG
mouse hearts by 70% according to the experimental finding by Gong et al.94.
Experimental data with TG mice overexpressing 2-ARs demonstrate a 44% reduction of the
expression of phospholamban (PLB)95. This should result in a smaller inhibition of the SERCA
pump in TG mice. To estimate the change in the pumping rate of the SERCA pump due to smaller
PLB expression, we used experimental data by Luo et al.96 and Kadambi et al.97. Luo et al.96
measured the dissociation constant for the SERCA pump, Km,up, in WT and PLB-knockout
mice (0.24±0.02 µM and 0.11±0.01 µM for [Ca2+]i, respectively). Kadambi et al.97 measured Km,up in WT
mice and mice with a two-fold overexpression of PLB, which were equal to 0.27±0.01 µM and 0.48±0.04
µM for [Ca2+]i, respectively. Our interpolation of these data resulted in ~20% reduction of K m,up for TG
mice overexpressing 2-ARs, which was implemented in the new mathematical model.

Further, most experimental data shows a decrease in the magnitude of the L-type Ca2+ current ICaL
in TG mice overexpressing 2-ARs (~40% reduction98, ~32% reduction43, ~26% reduction99, and
no change63). In our mathematical model we implemented the average value of these experimental
data which corresponds to a 24% reduction in ICaL.

91

Figure 4.1 A schematic representation of the combined β1- and β2-adrenergic signaling systems in mouse
ventricular myocytes overexpressing β2-adrenergic receptors. The cell consists of three compartments
(caveolar, extracaveolar, and cytosol) related to the combined β1- and β2-adrenergic signaling systems.
The subspace volume (Vss) is localized in the extracaveolar compartment. The biochemical portions of the
combined β1- and β2-adrenergic signaling systems are the β1-adrenergic receptors (β1-AR), the β2adrenergic receptors (β2-AR), the α-subunit of stimulatory G-protein (Gsα), the α-subunit of inhibitory Gprotein (Giα), the βγ-subunit of Gs and Gi (Gβγ), the adenylyl cyclases of type 5/6 or 4/7 (AC5/6 or AC4/7,
respectively), the phosphodiesterases of type 2, 3, or 4 (PDE2, PDE3, or PDE4, respectively), the cyclic
AMP (cAMP), regulatory (R) and catalytic (C) subunits of protein kinase A holoenzyme, the protein kinase
A inhibitor (PKI), the G-protein-coupled receptor kinase of type 2 (GRK2), the protein phosphatases of
type 1 and 2A (PP1 and PP2A, respectively), the inhibitor-1 (I-1). Targets of the combined β1- and β2adrenergic signaling systems are in the caveolar (the fast Na+ current (INa), the L-type Ca2+ current
(ICaL,cav), the Na+/K+ pump (INaK) which is regulated by phospholemman (PLM), phosphodiesterases PDE2PDE4, and the time-independent K+ current (IK1)), the extracaveolar (the L-type Ca2+ current (ICaL,ecav), the
rapidly recovering transient outward K+ current (IKto,f), the ultrarapidly activating delayed rectifier K+
current (IKur), ryanodine receptors (RyRs), and phosphodiesterases (PDE2, PDE4)), and cytosol
(phospholamban (PLB) and troponin I (TnI)). Stimulatory links are shown by black arrows and inhibitory
links are shown by red dashed lines with balls. Other transmembrane currents are the sarcolemmal Ca2+
pump (Ip(Ca)), the Na+/Ca2+ exchanger (INaCa), the rapid delayed rectifier K+ current (IKr), the
noninactivating steady-state voltage activated K+ current (IKss), the Ca2+ and Na+ background currents (ICab
and INab), which are not affected by the combined β1- and β2-adrenergic signaling systems. The Ca2+ fluxes
are uptake of Ca2+ from the cytosol to the network sarcoplasmic reticulum (NSR) (Jup) by the SERCA pump
and Ca2+ release from the junctional sarcoplasmic reticulum (JSR) (Jrel) through the ryanodine receptors.
[Ca2+]i, [Na+]i, and [K+]i are the intracellular Ca2+, Na+, and K+ concentrations in the caveolar,
extracaveolar, and cytosol; [Ca2+]o, [Na+] o, and [K+]o are the extracellular Ca2+, Na+, and K+
concentrations. Proteins which characteristics are modified in transgenic mouse overexpressing β 2adrenergic receptors are shown in green.
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As most experimental data on TG mice were obtained with stimulation by zinterol, we changed
the affinity constants of the ligand L for 1-ARs and 2-ARs. The new constants are Kβ1,L = 1.0
µM and Kβ1,H = 1.0 µM for 1-ARs and Kβ2,H = 0.04 µM and Kβ2,F = 0.04 µM for 2-ARs46. Finally,
we adjusted the activation rate constants for Gs and Gi proteins to reflect their changes in affinities.
To simulate the effects of isoproterenol, we used the values of affinities and rate constants as in
the original model92. All changes made to the model by Rozier and Bondarenko92 are shown in
Table 2.
PKA target proteins are located in different compartments in the same manner as in
reference 92. The fast Na+ current, INa, 20% of the L-type Ca2+ channels (the L-type Ca2+ current,
ICaL), phospholemman (PLM), which regulates the Na+-K+ pump, INaK, and the time-independent
K+ current, IK1, are localized in the caveolar compartment; the ultra-rapidly activating delayed
rectifier K+ current, IKur, the rapidly inactivating transient outward K+ current, IKto,f, 80% of the Ltype Ca2+ channels, and the ryanodine receptors, RyRs, are localized in the extracaveolar
compartment; and phospholamban and troponin I are localized in the cytosolic compartment.
Detailed model descriptions can be found in the previously published papers27, 92.
4.2.2 Method of simulation
The mathematical model consists of 149 ordinary differential equations, which were solved by
a fourth-order Runge-Kutta method, with two different time steps. A relatively small time step of
0.000002 ms was used during a 10 millisecond interval after the initiation of the stimulus current;
for all other times we used the time step 0.0001 ms. Simulation of the cellular behavior without
electrical stimulation was performed with time step of 0.1 ms. The model equations were
implemented in FORTRAN 90. All simulations were performed on a single processor under SUSE
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Table 2 Differences between current TG mouse model and the WT mouse model by Rozier and
Bondarenko92.
WT cell model
Current TG
Parameter definition
Rozier and
cell model
Bondarenko
[2017]
β-adrenergic receptor module
[Rβ1]tot
Kβ1,L
Kβ1,H

Total β1-adrenergic receptor concentration

0.00000103 μM

N/A

1.0 μM

N/A

1.0 μM

4.9 s–1

0.98 s–1

0.0053 μM

1.06 μM

10.086 μM

17.1462 μM

N/A

0.04 μM

0.0189 μM

0.04 μM

2.0 s–1

0.26 s–1

0.050 s–1

0.0065 s–1

Low affinity constant of β1-adrenoceptor for zinterol
High affinity constant of β1-adrenoceptor for zinterol

kact1,Gsβ1

Activation rate for Gs by β1-ARs high affinity
complex

[Rβ2]tot

Total β2-adrenoceptor concentration

[Gi]tot

Total concentration of Gi protein

Kβ2,H

High affinity constant of β2-adrenoceptor for zinterol

kact1,Gi

High affinity constant of phosphorylated β2adrenoceptor/ligand
Activation rate for Gi by high affinity complex

kact2,Gi

Activation rate for Gi by low affinity complex

Kβ2,F

0.0103 μM

L-type Ca2+ current module

GCaL

Specific maximum conductivity for L-type Ca2+
channel (non-phosphorylated)

0.3772 mS/μF

0.2791 mS/μF

GCaLp

Specific maximum conductivity for L-type Ca2+
channel (phosphorylated)

0.7875 mS/μF

0.5828 mS/μF

0.41 μM

0.328 μM

0.31 μM

0.248 μM

Phospholamban module
K mnp,up
K mp,up

Half-saturation constant for SR Ca2+-ATPase pump
(non-phosphorylated)
Half-saturation constant for SR Ca2+-ATPase pump
(phosphorylated)
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Linux 11 on a Dell Precision Workstation T3500 with a six-core Intel Xeon CPU W3670 (3.2
GHz, 12 GB RAM). The model is developed for a room temperature of 25ºC (T = 298ºK). Initial
conditions were obtained by running the program code without electrical stimulations for about
10,000 seconds to ensure quasi-steady-state. Action potentials were initiated by a stimulus current
(Istim = 80 pA/pF, τstim = 1 ms) with the frequency 0.5 Hz (electrical stimulation).

4.3

Results
In this chapter, we developed a mathematical model of the ventricular myocyte from TG mice

overexpressing β2-adrenergic receptors. The model includes three major subcellular
compartments, caveolar, extracaveolar, and cytosol, and β2-ARs are localized in the membranes
of caveolar (99%) and extracaveolar (1%) compartments. In the model, we inhibited β1-ARs
according to the experimental finding that they are inactive100. The model was explored to
investigate the effects of stimulation of β2-ARs with zinterol under different physiological
conditions, such as control, inhibition of Gi by PTX or inhibition of β2-ARs by ICI 118,551. Under
these multiple physiological conditions, we investigated: 1) compartmentalization of cAMP
generation and PKA activation; 2) the effects on the L-type Ca2+ current; 3) the alterations of the
action potentials and ionic currents; 4) the effects on [Ca2+]i transients; and 5) the effects of ICI
118,551 on the cellular activity.

4.3.1 Adenylyl cyclase activity, cAMP and PKA dynamics
Experimental data consistently shows an increased level of the background adenylyl cyclase
activity in TG mice overexpressing β2-ARs as compared to WT mice (~150-200 level of
overexpression, Fig. 4.2A)29,91. Upon stimulation with isoproterenol, the total AC activity
increases in both WT and TG mice, however, to different degrees at maximum stimulation with
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100 µM isoproterenol. The experimental maximum AC activity is larger for WT mice than that
for TG mice overexpressing β2-ARs91 (however, see data by Milano et al.29, where total AC
activity is somewhat larger in TG mice). Our model reproduced this dependence of AC activity as
functions of isoproterenol in WT and TG mice (Fig. 4.2B). Our simulations show larger AC
activity in TG mice without application of isoproterenol, and this relation reversed at high dose of
isoproterenol (100 µM).
Figure 2C demonstrates the comparison of the absolute total AC activities in WT and TG mice
in control (0 µM isoproterenol) and after stimulation with 100 µM isoproterenol. Our simulation
data for WT mice corresponds well to the data by Lemire et al.51, which was normalized
(experimentally measured AC activities can vary substantially, we have chosen the most frequently
occurring values for fitting our simulations). The experimental data on the total AC activities by
Liggett et al.91 for WT mice is somewhat larger, but demonstrates a similar tendency to increase.
For TG mice, our simulations demonstrate larger values of AC activity in control and smaller
values at maximum stimulation with isoproterenol (Fig. 4.2C).
An interesting feature of TG mice overexpressing β2-ARs is that the high level of
overexpression results in the appearance of a constitutively active (phosphorylated) fraction of β2ARs100. This fraction is quite high and approaches 100% of the concentration of β2-ARs even at
low doses of isoproterenol100. We estimated fractions of phosphorylated β2-ARs using our models
for WT and TG mice under different physiological conditions (Fig. 4.2D). For WT mice, the
estimations for control conditions and upon inhibition of Gi demonstrated ~57% and ~78% of
phosphorylated β2-ARs. For TG mice, the fraction of phosphorylated β2-ARs is larger for control
and upon inhibition of Gi (~77% and ~82%, respectively). This fraction does not change
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dramatically upon stimulation with 1 µM zinterol (81.5% and 84% for 1 µM zinterol and PTX +
1 µM zinterol, respectively, Fig. 4.2D).
cAMP concentrations in TG mice display different dynamics in the three major cellular
compartments under different physiological conditions. cAMP dynamics is defined by cAMP
production by adenylyl cyclases, cAMP degradation by phosphodiesterases, and cAMP diffusion

Figure 4.2 Adenylyl cyclase activities and phosphorylation of β2-adrenoceptors. Panel A: Experimental
total adenylyl cyclase activities in WT mice (filled squares) and TG mice overexpressing β2-adrenoceptors
(unfilled triangles) as functions of isoproterenol concentration91. Panel B: Simulated total adenylyl cyclase
activities in WT mice (solid line) and TG mice overexpressing β2-adrenoceptors (dashed line) as functions
of isoproterenol concentration. Panel C: Simulated and experimental total AC activities in WT and TG
mice for control (0 µM isoproterenol) and after application of 100 µM isoproterenol. Experimental data
for WT mice are from51; experimental data for WT and TG mice are from91. Panel D: Simulated fractions
of phosphorylated β2-adrenoceptors in WT (black bars) and TG (gray bars) mice under different
physiological conditions. Data are simulated for control (C), after application of PTX (PTX), after
application of 1 µM zinterol (Zint 1 µM), and after application of PTX and 1 µM zinterol (PTX + Zint 1
µM).

97

between intracellular compartments. Figure 4.3 shows the simulated time courses of cAMP
concentrations in different subcellular compartments in control (red lines), upon inhibition of Gi
with PTX (cyan lines), upon stimulation with 1 µM zinterol (green lines), and upon stimulation
with 1 µM zinterol in the presence of PTX (blue lines). The modeling data shows different levels
of cAMP in different compartments in control. The largest level of cAMP is in the caveolar
compartment where most (99%) β2-ARs are localized. Inhibition of Gi with PTX increases cAMP
levels in all compartments. Simulated cAMP concentration on the cellular level increases as well
from 0.36 µM to 0.78 µM (2-fold increase) (Fig. 4.3D). Myocyte stimulation with 1 µM zinterol
increases cAMP level by about two-fold on the cellular level, with the significantly larger increase
in the caveolar compartment (Fig. 4.3A). The most significant cAMP increase was obtained with
1 µM zinterol in the presence of PTX in all compartment. In this case, the cAMP transient achieves
~2.5 µM at the cellular level, which is close to the cAMP concentrations obtained with 1 µM
isoproterenol in WT mice27. Note that in TG mice, cAMP production is due to the activation of
β2-ARs, because β1-ARs are silent100, while in WT mice cAMP is mostly produced by the
activation of β1-ARs, because β2-ARs are silent. Such a behavior of cAMP is reproduced by our
model for TG mice and by the Bondarenko model27 for WT mice.
The time behavior of the catalytic subunit of PKA is similar to that for cAMP (Fig. 4.4).
Significantly higher concentration of the catalytic subunit of PKA is generated by the TG mouse
model in the caveolar compartment even in control due to a significantly higher concentration of
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Figure 4.3 cAMP dynamics in mouse ventricular myocytes overexpressing β2-adrenoceptors. (Panel A),
extracaveolar (Panel B), and cytosolic (Panel C) compartments, as well as in the whole cell (Panel D).
Simulations were performed for four cases: control, application of 1 µM zinterol, application of PTX, and
application of PTX + 1 µM zinterol.
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Figure 4.4 PKA catalytic subunit dynamics in mouse ventricular myocytes overexpressing β2adrenoceptors. Simulated PKA catalytic subunit concentrations are shown as functions of time in the
caveolar (Panel A), extracaveolar (Panel B), and cytosolic (Panel C) compartments, as well as in the
whole cell (Panel D). Simulations were performed for four cases: control, application of 1 µM zinterol,
application of PTX, and application of PTX + 1 µM zinterol.

cAMP in that compartment (Fig. 4.4A). In addition, the concentration of the catalytic subunit of
PKA does not decrease in time in caveolar compartment, which results in a significant level of
phosphorylation of β2-ARs and leading to a significant fraction of constitutively active β2-ARs.
The PKA activity in other compartments is smaller. It increases upon inhibition of Gi as compared
to control in the extracaveolar and cytosolic compartments (Fig. 4.4B and 4.4C), as well as in the
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whole cell (Fig. 4.4D). Stimulation with 1 µM zinterol leads to a PKA activation which is similar
to PTX in most compartments and at the cellular level, except for the extracaveolar compartment,
where PKA activation with zinterol is about two-fold larger than that with PTX (Fig. 4.4B).

4.3.2 The effects on the L-type Ca2+ current
Experimental data consistently shows a decrease in the magnitude of the L-type Ca2+ current,
ICaL, in TG mice overexpressing 2-ARs as compared to WT mice43,98,99, with an average value of
decrease ~24%. In addition, ICaL does not change significantly in TG mice upon stimulation with
1 µM zinterol and inhibition with PTX59. However, the magnitude of the L-type Ca2+ current
significantly increases after the application of 1 µM zinterol in the presence of PTX59.
Figure 4.5 shows simulations of these experimental findings in WT and TG mice. The
magnitude of WT ICaL is ~6.63 pA/pF with voltage pulse to +10 mV, which is about 30% larger
than that from TG mice in control, ~5.10 pA/pF. Stimulation of β2-ARs in TG mice with 1 µM
zinterol increases the magnitude of ICaL by ~15% only (long dashed line in Fig. 4.5A), which is
within the accuracy of the experimental measurement59. Similarly, inhibition of Gi with PTX also
slightly increases the L-type Ca2+ current magnitude by ~8% (medium dashed line in Fig. 4.5A).
However, application of 1 µM zinterol plus PTX leads to a much larger increase in ICaL, by ~40%,
which is
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Figure 4.5 The effects of stimulation of β2-ARs on the L-type Ca2+ current. Currents are obtained by voltage
pulses from −70 mV to +50 mV (in 10-mV increments) from a holding potential of −80 mV and without
Ca2+-induced Ca2+ release to account for heavy buffering conditions. Panel A: Simulated current-voltage
relationships obtained for several physiological conditions: control (solid lines), after application of 1 μM
zinterol (long dashed lines), after inhibition of Gi without isoproterenol (medium dashed lines), after
application of 1 μM zinterol with inhibition of Gi (dotted lines). Panel B: Simulated (black bars) and
experimental (gray bars) maximum magnitude of the L-type Ca2+ current under the same conditions as in
Panel A. Experimental data are from Zhou et al.59.

consistent with the experiments by Zhou et al.59 (~48% increase). Comparison of the
experimental59 and simulation data under different physiological conditions is shown in Fig. 4.5B.
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Thus, our model describes well the effects of stimulation of β2-ARs with 1 µM zinterol on the
L-type Ca2+ current in TG mouse ventricular myocytes overexpressing β2-ARs. Simulations show
that the effects of β2-ARs on the L-type Ca2+ current can be revealed by stimulation in the presence
of PTX.

4.3.3 The effects on [Ca2+]i transients
Experimental data demonstrates that intracellular [Ca2+]i transients in TG mice overexpressing
β2-ARs is larger than in WT mice under control conditions67. Stimulation of β2-ARs with zinterol
in TG mice overexpressing β2-ARs does not show remarkable effects on [Ca2+]i without the
inhibition of Gi. However, experimental data on the magnitude of myocyte contraction, which is
dependent on the magnitude of [Ca2+]i transients, demonstrates a trend towards an increase even
without Gi inhibitor PTX67. The effect of zinterol is more pronounced in the presence of PTX,
when significant difference between unstimulated and stimulated cells is observed.
Figure 4.6A shows simulated [Ca2+]i transients obtained after 300 s stimulation for WT and TG
mice under different physiological conditions. [Ca2+]i transients are larger in TG mice (black solid
line in Fig. 4.6A) than in WT mice (red solid line in Fig. 4.6A), which is consistent with
experimental findings67. Application of PTX or 1 µM zinterol increases [Ca2+]i transients in TG
cells by ~24% and ~36%, respectively. Simultaneous application of PTX and 1 µM zinterol
resulted in a much larger increase in [Ca2+]i (by ~79%, dotted line in Fig. 4.6A).
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Figure 4.6 [Ca2+]i transients in mouse ventricular myocytes under different physiological conditions. Panel
A: Simulated [Ca2+]i transients obtained in WT mice for control (red solid line) and TG mice for control
(black solid line), after application of 1 μM zinterol (black long dashed line), after inhibition of Gi (PTX)
(black short dashed line), after application of 1 μM zinterol with the inhibition of Gi (black dotted line).
Panel B: Simulated data on a relative increase in [Ca2+]i transients and experimental data on a relative
increase in [Ca2+]i transients and myocyte contraction for WT and TG mice. Simulated data are obtained
for the same physiological conditions as in Panel A. Experimental data by Grandy et al.98 and Zhou et al.63
are obtained for [Ca2+]i transients; experimental data by Xiao et al.67 and Zhou et al.63 are obtained for
myocyte contraction. Panel C: Simulated sarcoplasmic reticulum Ca2+ concentrations [Ca2+]JSR (black
bars) for the same physiological conditions as in Panel A. Experimental data (gray bars) for WT and TG
mice are obtained by Grandy et al.98. [Ca2+] i transients and [Ca2+]JSR are shown after 300 s stimulation
with 0.5 Hz.

Detailed comparisons of the simulated and experimental data on the maximal [Ca2+]i transients
in WT and TG mouse ventricular myocytes under different physiological conditions is shown in

104

Fig. 4.6B. In addition to [Ca2+]i transients, we also show data on myocyte contraction, which the
behavior is quite similar to [Ca2+]i. The available experimental data for all simulated physiological
conditions are from one source67. The data in Fig. 4.6B are normalized to the magnitude of [Ca2+]i
transients in TG mice in control. Simulation data on [Ca2+]i transients for WT and TG mice upon
stimulation of β2-ARs under different physiological conditions. Control conditions compare well
to the corresponding experimental data67,98. The experimental data on normalized myocyte
contraction is somewhat smaller for WT mice under control than the data on [Ca2+]i63,67. Our
simulation data are in line with the experimental data on myocyte contraction upon stimulation
with 1 µM zinterol (without PTX), application of PTX, and combined application of 1 µM zinterol
plus PTX (Fig. 4.6B). Unfortunately, consistent experimental data on those various physiological
conditions for [Ca2+]i is not available.
We also investigated the sarcoplasmic reticulum (SR) Ca2+ content ([Ca2+]JSR) under different
physiological conditions (Fig. 4.6C). Experimental data shows significantly smaller (by ~37%) SR
content in WT mice as compared to TG mice98. Our mathematical model for WT mice92 and model
for TG mice overexpressing β2-ARs reproduced this difference. In addition, we simulated the SR
Ca2+ content after application of 1 µM zinterol (without PTX), PTX, and 1 µM zinterol plus PTX
(Fig. 4.6C). The simulations demonstrate consistent, but rather small increase in [Ca2+]JSR under
these different physiological conditions (~16%-19% increase).
Thus, model simulations of [Ca2+]i transients in WT and TG mouse ventricular myocytes
reproduces their differences under control conditions, and predict a moderate increase in [Ca2+]i
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4.3.4 The effects on mouse action potential
There are virtually no experimental measurements of the action potential characteristics in TG
mice overexpressing β2-ARs, except for the only paper by Zhou et al.63. Zhou et al.63 have found
that there is no significant difference in APD50 between WT and TG mice. However, their data
indicates a significant increase in APD90 in TG mice as compared to WT mice (by ~2 fold).
Because there were no effects of ICI 118,551 found on APD90 in the TG mouse cell, it was
concluded that such APD90 prolongation is not directly due to the overexpression of β2-ARs.
Figure 4.7 demonstrates the action potentials for WT and TG mice overexpressing β2-ARs. Quite
small difference between WT and TG mouse action potentials were found under control conditions
(~10% decrease in APD50 and ~6% increase in APD90 in TG mice as compared to WT mice).
Simulations with TG mice demonstrate virtually no change in APD50 upon stimulation with 1 µM
zinterol (without PTX) or application of PTX (Fig. 4.7C). The combined application of 1 µM
zinterol plus PTX resulted in ~14% increase in APD50 as compared to control. In contrast, APD90
in TG mice shows and increase by ~14%, ~10%, and ~21% upon application of 1 µM zinterol
(without PTX), PTX, and combined application of 1 µM zinterol plus PTX, respectively (Fig.
4.7D).
The changes in ionic currents underlying the TG mouse action potential in control and after
application of 1 μM zinterol + PTX are shown in Fig. 4.7E and 4.7F, respectively. The increase in
APD50 after application of 1 μM zinterol + PTX is a result of changes in major repolarization
currents: a decrease in IKto,f and an increase in ICaL tends to prolong the action potential, but an
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Figure 4.7 Mouse action potentials in WT and TG mice, and APD50 and APD90 under different physiological
conditions. Panel A: Simulated mouse action potentials for WT control (red solid line), for TG control
(black solid line), after application of 1 µM zinterol (black long dashed line), upon inhibition of Gi (black
short dashed line), and after application of 1 µM zinterol and inhibition of Gi (black dotted line). Panel B
shows details of repolarization in the voltage range from −80 mV to −40 mV. Panels C and D show
simulated APD50 and APD90, respectively, for the same physiological conditions as in Panel A. Panel E:
Simulated major ionic currents underlying TG mouse action potential in control. Panel F: Simulated major
ionic currents underlying TG mouse action potential after the application of 1 μM zinterol and the inhibition
of Gi with PTX. In Panels A-D, action potentials, APDs, and ionic currents are obtained after 300 s
stimulation with 0.5 Hz.

increase in IKur tends to reduce the action potential. These tendencies continue towards later
repolarization stages resulting in prolongation of APD90 as well.
Thus, our modeling data suggest that the most remarkable prolongation of the action potential
duration in TG mice overexpressing β2-ARs can be observed with the application of zinterol in the
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presence of PTX. The larger prolongation is observed for APD90 as compared to APD50. The
mechanism of this prolongation is discussed above. Further experiments are necessary to verify
our model predictions.

4.3.5 The effects of β2-adrenoceptor inverse agonist ICI 118,551 in TG mouse ventricular
myocytes
Our mathematical model allows for evaluation of the effects of β2-AR inverse agonist ICI
118,551 on the cellular activity of ventricular myocyte from TG mice. As we and others have
shown42,92 that β1-ARs are primarily responsible for the changes in AP and [Ca2+]i in WT mice. In
TG mice overexpressing β2-ARs, the application of ICI 118,551 revealed a major role of β2-ARs
in the changes in cardiac myocyte activities. Ventricular myocytes from TG mice demonstrate
larger background AC activity as compared to WT cells29. Application of ICI 118,551 reduced AC
activity in the TG cells by about two fold100, and cAMP level in the TG cells can be comparable
to that in WT cells59. Our model was able to reproduce these effects. Figure 4.8A shows
simulations of AC activities in WT mice and TG mice before and after the application of ICI
118,551 normalized to AC activity in TG mice in control. Application of ICI 118,551 was
simulated by a reduction of β2-AR concentration by 10,000. Simulated TG cells in control
demonstrate increased AC activity as compared to WT cells. Application of ICI 118,551 does not
affect WT cells (data not shown), but it significantly reduced AC activity in TG cells. Such a
reduction is comparable to the experimental data by Bond et al.100.
We also simulated the effects of ICI 118,551 in PTX-pretreated TG ventricular myocytes to
reproduce the effects in the experiments by Xiao et al.67. As Xiao et al.67 measured myocyte
contraction, which is closely related to the magnitude of [Ca2+]i transient, we investigated the
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behavior of [Ca2+]i under three different physiological conditions: after application of PTX, after
an application of 1 µM zinterol in PTX-pretreated cells, and upon inhibition of the effects of 1 µM
zinterol in PTX-pretreated cells. The simulations show an increase in [Ca2+]i transient after
application of 1 µM zinterol in PTX-pretreated cells, which is suppressed by ICI 118,551 (Fig.
8B). Comparison of the simulations with the experiments by Xiao et al.67 on TG myocyte
contraction demonstrates qualitative agreement.
As TG ventricular myocytes overexpressing β2-ARs show an increased AC activity in
control that leads to increased activation of PKA, it is interesting to simulate the effects of ICI
118,551 on the action potential and [Ca2+]i transient in TG myocytes under control conditions.
These data are shown in Fig. 4.9. It is seen that the application of ICI 118,551 affects mostly the
late stage of repolarization in the action potential (Fig. 4.9A), which is due to the larger reduction
of the inward L-type Ca2+ current ICaL comparing to that of the transient outward K+ current IKto,f
(Figs. 4.9C and 4.9D). The application of ICI 118,551 also causes a decrease in [Ca2+]i transients
in TG myocytes (Fig. 4.9B).
Thus, our simulations suggest that an increased background [Ca2+]i transient and myocyte
contraction is primarily due to the activity of β2-ARs in TG mice. [Ca2+]i transient and myocyte
contraction can be reduced to the values comparable to WT cells after application of β2-AR
inverse agonist ICI 118,551.
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Figure 4.8 Simulation of the effects of selective inhibitor ICI 118,551 on the behavior of mouse ventricular
myocytes overexpressing β2-adrenoceptors. Panel A: Simulated (black bars) and experimental (gray bars)
by Bond et al.100 normalized AC activities for WT mice (WT Control), TG mice (TG Control), and TG mice
after application of ICI 118,551 (TG ICI 118,551). Data are normalized to TG (control). Panel B:
Simulated [Ca2+] i transients in TG mouse ventricular myocytes upon application of PTX, PTX + 1 μM
zinterol, and PTX + 1 μM zinterol + ICI 118,551. Panel C: Comparison of simulated peak amplitudes of
[Ca2+]i transients (black bars) and experimental peak myocyte contractions (gray bars)67 in TG mice upon
application of PTX, PTX + 1 μM zinterol, and PTX + 1 μM zinterol + ICI 118,551.
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Figure 4.9 Mouse action potentials, [Ca2+]i transients, and ionic currents in TG mice in control and after
application of ICI 118,551. Panel A: Simulated TG mouse action potentials for control (solid line) and
after application of ICI 118,551 (dashed line). Panel B: Simulated TG mouse [Ca2+]i transients for control
(solid line) and after application of ICI 118,551 (dashed line). Panel C: Simulated major ionic currents
underlying TG mouse action potential in control. Panel D: Simulated major ionic currents underlying TG
mouse action potential after the application of ICI 118,551. In Panels A-D, action potentials, [Ca2+]i
transients, and ionic currents are obtained after 300 s stimulation with 0.5 Hz.

4.4

Discussion
In this chapter, a new compartmentalized mathematical model for TG mouse ventricular

myocytes overexpressing 2-adrenergic receptors is developed. The model is based on the
previously published model of the combined 1- and β2-adrenergic signaling systems92, which
includes compartmentalization and the effects on the action potential, ionic currents, and Ca2+
dynamics. The new model was explored to investigate the effects of the overexpression of 2-ARs
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on the regulation of cardiac cells upon stimulation with isoproterenol and zinterol under different
physiological conditions. The model was able to simulate increased AC activities in TG cells and
the effects of isoproterenol on AC activity. We found that zinterol causes significant effects on the
L-type Ca2+ current only in the cells pretreated with Gi inhibitor PTX. The model allows for
determination of the mechanisms of action potential prolongation and increase in [Ca2+]i transients
under stimulation of 2-ARs with zinterol, inhibition of Gi with PTX, and stimulation of 2-ARs
with zinterol in the presence of PTX. In addition, we simulated the effects of 2-AR inverse agonist
ICI 118,551 on the adenylyl cyclase activity, action potential, and [Ca2+]i transients in ventricular
cells overexpressing 2-adrenergic receptors.

4.4.1 The effects of the overexpression of β2-adrenergic receptors in mouse hearts
β1- and β2-adrenergic receptors play different roles in the heart. Experimental data shows that
cardiac-specific overexpression of β1-ARs results in hypertrophy, which lead to heart failure28. On
the other hand, moderate overexpression of β2-ARs improved cardiac function29. To gain insights
into the mechanisms of these different physiological effects, multiple experiments were performed
on activation and inhibition of β1-ARs and β2-ARs in WT and TG mice and isolated myocytes.
β1- and β2-adrenergic receptors cause different physiological effects on the action potential,
ionic currents, and Ca2+ dynamics in WT mouse ventricular myocytes. Stimulation of β1-ARs with
isoproterenol activates the Gs-mediated signaling pathway and leads to major inotropic effects in
WT cells such as a large increase in [Ca2+]i transient and myocyte contraction. Inhibition of β1ARs with antagonist CGP-20712A eliminates the effect of stimulation, while the effects of inverse
agonist of β2-ARs ICI-118,551 does not change the effect of stimulation. On the other hand,
stimulation of β2-ARs with isoproterenol in the presence of CGP-20712A in WT cells activates
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both Gs- and Gi-mediated signaling systems, resulting in less pronounced effects or no effect at
all67. The effects of β2-ARs in WT myocytes can be revealed upon inhibition of Gi with PTX. TG
mouse ventricular myocytes overexpressing β2-ARs demonstrate different behaviors. Stimulation
of TG mouse cells with isoproterenol in the presence of PTX shows a marked increase in the
magnitude of myocyte contraction59. Application of β1-AR antagonist CGP-20712A does not
cause significant effects on contraction, while application of inverse agonist of β 2-ARs ICI118,551 abolishes the effect of isoproterenol. Thus, experimental data shows that β1-ARs produces
pronounced effects in WT cells and are silent in TG mice overexpressing β2-ARs, however, β2ARs produce pronounced effects in TG cells overexpressing β2-ARs and are silent in WT mice in
control conditions.
Our mathematical model for WT cells92 and the model proposed in this paper for TG mice are
able to simulate the different behaviors of these cell types. We found92 that in WT ventricular
myocytes, isoproterenol produced a significant increase in ICaL and [Ca2+]i transients when β2-ARs
were blocked, and cause virtually no effects when β1-ARs are blocked. As most of the experimental
data on TG mice are obtained with zinterol, we simulated the effects of this β2-AR agonist within
our new TG model. We found that the effect of 1 µM zinterol on the L-type Ca2+ current in TG
mice is significant only in the presence of PTX (~40%). Application of PTX or 1 µM zinterol
caused less pronounced effects on ICaL (~8% and ~15%, respectively). While some noticeable
effects of the application of PTX or 1 µM zinterol on [Ca2+]i transients and myocyte contraction
in TG cells are found, the effects are more significant in the presence of both pharmacological
interventions. Finally, simulations of the effects of inverse agonist ICI-118,551 show that the
increase in the background [Ca2+]i transients and myocyte contraction in TG cell as compared to
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WT cells is due to the overexpression of β2-ARs. These simulations confirmed the corresponding
experimental data59,67.
There is virtually no data on the effects of the overexpression of β2-ARs on the cardiac action
potential. The action potential in TG mice overexpressing β2-ARs was investigated only by Zhou
et al.63. They found that APD50 was identical for WT and TG mice, however, APD90 was
significantly increased in TG cells. Because there were no significant effects of ICI 118,551 on
the action potential, Zhou et al.63 suggested that APD90 prolongation in TG mice is not directly
due to β2-AR overexpression. Our simulations show that APD50 in TG cells is ~10% shorter than
that in WT mice, but it does not change upon the application of PTX or 1 µM zinterol. APD90 is
slightly more prolonged in TG mice as compared to WT mice (~6%), however, application of
PTX, 1 µM zinterol, or 1 µM zinterol plus PTX increases APD90 in TG mice by ~10% - 21%.

4.4.2 Model limitations
Our mathematical model of the mouse ventricular myocyte overexpressing β2-adrenergic
receptors was derived from the previously published model of the combined β1- and β2-adrenergic
signaling system92, which was extensively verified by experimental data. In addition, this new
model describes multiple experiments obtained in TG mice overexpressing β2-ARs. However, it
has the following limitations: 1) the model relies on the low accuracy of biochemical and
physiological experiments, which can vary by multiple folds; 2) not all model parameters were
measured directly in the experiments and were adjusted to fit the experimental data; 3) the model
does not include the possible effects of the CaMKII-mediated signaling system. Nevertheless, the
model replicates the published experimental data quite well and provides some insights into the
mechanisms that lead to the differences between WT and TG mice overexpressing β2-ARs.
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4.5

Conclusions
We developed a comprehensive experimentally-based compartmentalized mathematical model

of the mouse ventricular myocytes overexpressing β2-adrenergic receptors. We found that most of
the β2-adrenergic receptors are active in control conditions in TG mice. The model describes the
dynamics of major signaling molecules in different subcellular compartments; modifications of
action potential shape and duration; and [Ca2+]i dynamics upon stimulation of β2-adrenergic
receptors in control, after application of PTX, upon stimulation with zinterol, and upon stimulation
with zinterol in the presence of PTX. The model also describes the effects of inverse agonist ICI118,551 on cAMP production, action potential, and [Ca2+]i transients. The simulation results are
compared to the experimental data obtained in the ventricular myocytes from TG mice.
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APPENDIX

MODEL EQUATIONS AND PARAMETERS.
Mathematical model of the combined β1- and β2-adrenergic signaling system consists of the model equations
(A.1)-(A.125) and model parameters presented in this Appendix plus 238 model equations (A.64)-(A.301) and model
parameters from Ref. 27.

BIOCHEMICAL PART
Cell compartments

Parameter

Definition

Value

Reference

Acap

Capacitive membrane area

1.534104 cm2

Bondarenko et al. (101)

Vcell

Cell volume

38.00106 μl

Bondarenko et al. (101)

Vcyt

Cytosolic volume

25.84106 μl

Bondarenko et al. (101)

VJSR

Junctional SR volume

0.1210-6 l

Bondarenko et al. (101)

VNSR

Network SR volume

2.09810-6 l

Bondarenko et al. (101)

Vss

Subspace volume

1.48510-9 l

Bondarenko et al. (101)

Vcav

Caveolar volume

0.02Vcell

Heijman et al. (26)

Vecav

Extracaveolar volume

0.04Vcell

Heijman et al. (26)

The protein P concentrations in the cell ([P]cell), caveolar, extracaveolar, and cytosol

cav

cav
P

cell

[P]

f

[P]

[P]ecav

f Pecav [P]cell

Vcell
Vcav
Vcell
Vecav

(A.1)
(A.2)
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cyt

[P]

(1 f

cav
P

f

ecav
P

cell

) [P]

Vcell
Vcyt

(A.3)

β1- and β2-adrenergic receptor module

Parameter

Definition

Value

Reference

[L]

Ligand concentration

0.100 M

[Rβ1]tot

Total β1-adrenoceptor concentration

0.0103 M

Hilal-Dandan et al. (32)

[Rβ2]tot

Total β2-adrenoceptor concentration

0.0053 M

Hilal-Dandan et al. (32)

f cav
1

Fraction of β1-adrenoceptors located

0.01

Rybin et al. (20)

in caveolar

f ecav
1

Fraction of β1-adrenoceptors located

Balijepali et al. (31)
0.5

Rybin et al. (20)

in extracaveolar

f cyt1

Fraction of β1-adrenoceptors located

Balijepali et al. (31)

f cyt1

1 f cav
f ecav
1
1

in cytosol

f cav
2

Fraction of β2-adrenoceptors located

0.99

Nikolaev et al. (34)

in caveolar

f ecav
2

Fraction of β2-adrenoceptors located

f ecav
2

1 f cav
2

in extracaveolar
[Gs]tot

Total concentration of Gs protein

2.054 M

Post et al. (19)

[Gi]tot

Total concentration of Gi protein

10.086 M

Rorabaugh et al. (33)

fGscav

Fraction of Gs protein located in

0.4

Rybin et al. (20)

0.4

Rybin et al. (20)

caveolar

fGsecav

Fraction of Gs protein located in
extracaveolar
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cyt
f Gs

Fraction of Gs protein located in

cyt
fGs

cav
ecav
1 fGs
fGs

cytosol

fGicav

Fraction of Gi protein located in

0.99

Nikolaev et al. (34)

caveolar

fGiecav

Fraction of Gi protein located in

fGiecav

1 fGicav

extracaveolar
Kβ1,L

Low affinity constant of β1-

0.567 M

Heijman et al. (26)

0.0617 M

Heijman et al. (26)

2.86 M

Bondarenko (27)

1.053 M

Green et al. (69)

0.0118 M

Green et al. (69)

5.86 μM

Rozier-Bondarenko (92)

0.0189 μM

Wenzel-Seifert and Seifert (102)

28.79 μM

Rozier-Bondarenko (92)

0.00081 μM1 s1

Freedman et al. (49)

0.0002025 s1

Bondarenko (27)

adrenoceptor for isoproterenol
Kβ1,H

High affinity constant of β1adrenoceptor for isoproterenol

Kβ1,C

Affinity constant of β1-adrenoceptor
for Gs protein

Kβ2,L

Low affinity constant of β2adrenoceptor for isoproterenol

Kβ2,H

High affinity constant of β2adrenoceptor for isoproterenol

Kβ2,C

Affinity constant of β2-adrenoceptor
for Gs protein

Kβ2,F

High affinity constant of
phosphorylated β2 receptor/ligand

Kβ2,A

Affinity constant of phosphorylated
β2 receptor/Gi protein

kPKA+

Rate of PKA phosphorylation of β1and β2- adrenoceptor

kPKA

Rate of PKA dephosphorylation of
β1- and β2- adrenoceptor
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kGRK2+

Rate of GRK2 phosphorylation of

0.000243 s1

Bondarenko (27)

kPKA

Bondarenko (27)

4.9 s1

Heijman et al. (26)

0.26 s1

Heijman et al. (26)

0.196 s1

Rozier-Bondarenko (92)

0.0104 s1

Rozier-Bondarenko (92)

β1- and β2- adrenoceptor
Rate of GRK2 dephosphorylation of

kGRK2

β1- and β2- adrenoceptor
Activation rate for Gs by β1-ARs

kact1,Gsβ1

high affinity complex
Activation rate for Gs by β1-ARs

kact2,Gsβ1

low affinity complex
Activation rate for Gs by β2-ARs

kact1,Gsβ2

high affinity complex
Activation rate for Gs by β2-ARs

kact2,Gsβ2

low affinity complex
khyd,Gs

Hydrolysis rate of Gsα-GTP

0.8 s1

Saucerman et al. (16)

kreas,Gs

Re-association rate for Gs

1200 μM1 s1

Saucerman et al. (16)

kact1,Gi

Activation rate for Gi by high

2.0 s1

Rozier-Bondarenko (92)

0.050 s1

Saucerman et al. (16)

affinity complex
kact2,Gi

Activation rate for Gi by low
affinity complex

khyd,Gi

Hydrolysis rate of Giα-GTP

khyd,Gs

Saucerman et al. (16)

kreas,Gi

Re-association rate for Gi

kreas,Gs

Saucerman et al. (16)

Caveolar
cav
[ R 1 ]tot

cav
[ R 2 ]tot

[Gs ]cav

Vcell
Vcav
Vcell
f cav
2 [ R 2 ]tot
Vcav
V
fGscav [Gs ]tot cell [Gs ]cav,GTP
Vcav
f cav
1 [ R 1 ]tot

(A.4)
(A.5)

[Gs ]cav,GDP

(A.6)
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[Gi ]cav

fGicav [Gi ]tot

[ R 1 ]cav
np ,tot

Vcell
Vcav

cav
[ R 1 ]tot

cav
2 np ,tot

[ R 1 ]cav
PKA,tot

cav
2 tot

[R ]

cav
2 PKA,tot

[R ]

(A.7)

[Gi ]cav,GTP [Gi ]cav,GDP

[R ]

cav
[ R 1 ]GRK
2,tot

(A.8)

cav
2 GRK 2,tot

[R ]

(A.9)

a cav

 2,i

K

1
K  2, L

 2, L

 [ L] K  2, F  [ L]

cav
bcav2,i  [Gi ]
 K 2,F  [ L]   K 2,F  [L][R 2 ]cavPKA,tot  K 2, A K 2,F  K 2, A K 2,F

ccav
 [ R 2 ]cav
PKA,tot K  2, A K  2, F
 2,i



cav
 2 PKA, f

[R ]

bcav2,i 

cav

2

 2,i

1  [R ]

cav
 2 PKA, f

[ LR 2 ] PKA 
cav

cav
i PKA

[ LR 2G ]

cav
i PKA

 1

[ L]



 K  2, A K  2, A K  2, F 

[ L][ R 2 ]cav
PKA, f
K  2, L





(A.11)

 4a cav
c cav
 2,i  2,i

cav
[Gi ]

[Gi ] f 

[ L]
K  2, L

(A.12)

2a cav
 2,i

cav

[ R 2G ]

b 

(A.10)

(A.13)

(A.14)

(A.15)

cav
[ L][ R 2 ]cav
PKA, f [Gi ] f

K  2, A K  2, F

cav
[ R 2 ]cav
PKA, f [Gi ] f

K  2, A

acav2,s  [ L]  K  1, H [ L]  K  2, H 

(A.16)

(A.17)

(A.18)
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cav
bcav2,s  [ L]  K  1, H [ L]  K  2, H  [ R 1 ]cav
np ,tot  [ R 2 ]np ,tot  


[ L]K  1,C K  1, H
 K  1,C K  1, H 
K  1, L




[ L]K  2,C K  2, H
 [ L]  K  2, H    K  2,C K  2, H 
K  2, L



cav
[Gs ]
[ L]  K  1,H [ L]  K  2,H 

(A.19)


[ L]K  2,C K  2, H
ccav2,s  [ L]  K  1, H   K  2,C K  2, H 

K  2, L


[ L ]  K



 2, H

  K


 1,C

K  1, H 


[ L]K  2,C K  2, H
  K  2,C K  2, H 
K  2, L



[ L]K  1,C K  1, H
cav
d cav2,s  [Gs ]
 K  1,C K  1, H 
K  1, L


bcav2,s
acav2,s

;

ccav2,s

q cav 

acav2,s

;


cav
cav
 [ R 1 ]np ,tot  [Gs ]  


[ L]K  1,C K  1, H 
cav
cav
 [ R 2 ]np ,tot  [Gs ]  
K  1, L



[ L]K  1,C K  1, H
 K  1,C K  1, H 
K  1, L


p cav 


 [ L]  K  1, H  


r cav 

d cav2,s
acav2,s






[ L]K  2,C K  2, H
K  2,C K  2, H 


K  2, L


(A.20)





(A.21)

(A.22)

Acav 

1
3q cav  ( p cav )2 

3

(A.23)

Bcav 

1
 2( pcav )3  9 pcav qcav  27r cav 
27

(A.24)

D

cav

( Acav )3 ( B cav ) 2


27
4

(A.25)
1/3

M

cav

 B cav

 
 Dcav 
 2


(A.26)

1/3

N

cav

 B cav

 
 Dcav 
 2


(A.27)
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If Dcav > 0 then y1cav  M cav  N cav ; y2cav  y3cav  0;
If Dcav = 0 then y1cav  M cav  N cav ; y2cav  y3cav  (M cav  N cav ) / 2;
If Dcav < 0 and Bcav > 0 then



 cav  arccos  



y1cav  2 

( B cav )2 / 4 

( Acav )3 / 27 

(A.28)

Acav
Acav
Acav
cos( cav ); y2cav  2 
cos( cav  2 / 3); y3cav  2 
cos( cav  4 / 3) (A.29)
3
3
3

If Dcav < 0 and Bcav ≤ 0 then



( B cav ) 2 / 4 

 ( Acav )3 / 27 



 cav  arccos 

(A.30)

cav
1

Acav
Acav
Acav
cav
cav
cav
cav
2 
cos( ); y2  2 
cos(  2 / 3); y3  2 
cos( cav  4 / 3) (A.31)
3
3
3

cav
i

y

y

p cav

, i  1, 2,3.
3

(A.32)

[Gs ]cav
 max{z1cav , z3cav , z3cav }
f

(A.33)

z

cav
i

cav
 1 np , f

[R ]

cav
 2 np , f

[R ]





[ R 1 ]cav
np ,tot


[ L]
[ L]
1
 [Gs ]cav

1 
f 
K K
 K  1,L
  1,C  1,H K  1,C


 
 

(A.34)


 
 

(A.35)

[ R 2 ]cav
np ,tot


[ L]
[ L]
1
 [Gs ]cav

1 
f 

 K  2,C K  2, H K  2,C
 K  2, L
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[ L] [ R 1 ]cav
np , f

cav
1 np

[ LR ]

K

cav
[ R 1 ]cav
np , f [Gs ] f

[ R 1Gs ]cav
np

K

[ LR 1G ]
[ LR 2 ]



K

cav
s np

[ LR 2G ]

(A.38)

1, H

(A.39)

cav
[ R 2 ]cav
np , f  [Gs ] f



dt
cav
d [ R 1 ]GRK
2,tot
dt

d [ R 2 ]cav
PKA,tot
dt
cav
d [ R 2 ]GRK
2,tot

dt

K

K  2, L

d [ R 1 ]cav
PKA,tot

d [Gs ]cav,GTP

1,C

[ L]  [ R 2 ]cav
np , f

[ R 2Gs ]cav

np

dt

(A.37)

1,C

cav
[ L] [ R 1 ]cav
np , f [Gs ] f

cav
s np

cav
np

(A.36)

1, L

(A.40)

K  2,C
cav
[ L]  [ R 2 ]cav
np , f  [Gs ] f

(A.41)

K  2,C K  2, H

kPKA [C ]cav [ R 1 ]cav
np ,tot

kGRK 2

cav
[ LR 1 ]np

cav
[ LR 1Gs ]np

kPKA [C ]cav [ R 2 ]cav
np ,tot

kGRK 2

[ LR 2 ]cav
np

kact 2,Gs 1[ R 1Gs ]cav
np

kPKA [ R 1 ]cav
PKA,tot

cav
kGRK 2 [ R 1 ]GRK
2,tot

kPKA [ R 2 ]cav
PKA,tot

[ LR 2Gs ]cav
np

cav
kGRK 2 [ R 2 ]GRK
2,tot

kact 2,Gs 2 [ R 2Gs ]cav
np

kact1,Gs 1[ LR 1Gs ]cav
np

(A.42)

(A.43)

(A.44)

(A.45)

kact1,Gs 2 [ LR 2Gs ]cav
np(A.46)

khyd ,Gs [Gs ]cav,GTP

d [Gs ]cav,GDP
dt
d [Gi ]cav,GTP
dt

khyd ,Gs [Gs ]cav,GTP

kreas ,Gs [G]cav [Gs ]cav,GDP

kact 2,Gi [ R 2Gi ]cav
PKA

kact1,Gi [ LR 2Gi ]cav
PKA

(A.47)

khyd ,Gi [Gi ]cav,GTP

(A.48)
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d [Gi ]cav,GDP

khyd ,Gi [Gi ]cav,GTP

dt

d [G ]cav
dt

kreas ,Gi [G]cav [Gi ]cav,GDP

(A.49)

kact 2,Gs 1[ R 1Gs ]cav
np

kact 2,Gs 2 [ R 2Gs ]cav
np

kact1,Gs 1[ LR 1Gs ]cav
np

kact1,Gs 2 [ LR 2Gs ]cav
np

kact 2,Gi [ R 2Gi ]cav
PKA

kact1,Gi [ LR 2Gi ]cav
PKA

kreas ,Gs [G ]cav [Gs ]cav,GDP

(A.50)

kreas ,Gi [G ]cav [Gi ]cav,GDP

Extracaveolar
ecav
[ R 1 ]tot

ecav
[ R 2 ]tot

[Gs ]ecav
[Gi ]ecav

Vcell
Vecav
Vcell
f ecav
2 [ R 2 ]tot
Vecav
V
fGsecav [Gs ]tot cell [Gs ]ecav
[Gs ]ecav
,GTP
,GDP
Vecav
V
fGiecav [Gi ]tot cell [Gi ]ecav
[Gi ]ecav
,GTP
,GDP
Vecav
f ecav
[ R 1 ]tot
1

[ R 1 ]ecav
np ,tot

ecav
[ R 1 ]tot

[ R 2 ]ecav
np ,tot

ecav
[ R 2 ]tot

a ecav

 2,i

1
K  2,L

K

 2, L

[ R 1 ]ecav
PKA,tot
[ R 2 ]ecav
PKA,tot



(A.53)

(A.54)
(A.55)

ecav
[ R 2 ]GRK
2,tot

(A.56)

 [ L] K  2,F  [ L]

cecav
 [ R 2 ]ecav
PKA,tot K  2, A K  2, F
 2,i

[R ]

(A.52)

ecav
[ R 1 ]GRK
2,tot

ecav
ecav
becav
2,i  [Gi ]  K  2, F  [ L]   K  2, F  [ L] [ R 2 ]PKA,tot  K  2, A K  2, F  K  2, A K  2, F

ecav
 2 PKA, f

(A.51)

becav
2,i 

b 

ecav 2

 2,i

2a ecav
 2,i

(A.57)

[ L]
K  2,L

(A.58)

(A.59)

 4a ecav
c ecav
 2,i
2,i

(A.60)
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ecav
[Gi ]



ecav

[Gi ] f

1  [R ]

ecav
 2 PKA, f

[ LR 2 ]ecav

PKA

ecav
i PKA

[ R 2 G ]

[ L][ R 2 ]ecav
PKA, f

[ LR 2 G ]

(A.62)

K  2,L



ecav
i PKA

(A.61)

 1

[ L]



 K  2, A K  2, A K  2,F 

ecav
[ R 2 ]ecav
PKA, f [Gi ] f

(A.63)

K  2, A



ecav
[ L][ R 2 ]ecav
PKA, f [Gi ] f

(A.64)

K  2, A K  2,F

aecav
2,s  [ L]  K  1, H [ L]  K  2, H 

(A.65)

ecav
ecav
becav
2,s  [ L]  K  1, H [ L]  K  2, H  [ R 1 ]np ,tot  [ R 2 ]np ,tot  


[ L]K  1,C K  1,H
 K  1,C K  1,H 
K  1,L




[ L]K  2,C K  2,H
 [ L]  K  2,H    K  2,C K  2, H 
K  2,L



ecav
[Gs ]
[ L]  K  1,H [ L]  K  2,H 


[ L]K  2,C K  2,H
cecav
K  2,C K  2,H 
2,s  [ L ]  K  1, H  

K  2,L


[ L]  K



 2, H

  K


 1,C

K  1,H 


[ L]K  1,C K  1,H
 K  1,C K  1,H 
K  1,L



 [ L]  K  1, H  


(A.66)

ecav
ecav
 [ R 1 ]np ,tot  [Gs ]  


[ L]K  1,C K  1,H 
ecav
ecav
 [ R 2 ]np ,tot  [Gs ]  
K  1,L


[ L]K  2,C K  2,H
  K  2,C K  2,H 
K  2,L



[ L]K  1,C K  1,H
ecav
d ecav
K  1,C K  1,H 
2,s  [Gs ] 

K  1,L







[ L]K  2,C K  2,H
  K  2,C K  2,H 
K  2,L


(A.67)





(A.68)
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p



ecav

becav
2,s
aecav
2,s

q

;

ecav



cecav
2,s
aecav
2,s

;

r

ecav



d ecav
2,s
aecav
2,s

(A.69)

Aecav 

1
 3qecav  ( pecav )2 
3

(A.70)

B ecav 

1
2( p ecav )3  9 p ecav q ecav  27r ecav 

27

(A.71)

D ecav 

( Aecav )3 ( B ecav )2

27
4

(A.72)
1/3

M

ecav

 B ecav

 
 Decav 
2



(A.73)
1/3

N

ecav

 B ecav

 
 D ecav 
2



(A.74)

If D ecav > 0 then y1ecav  M ecav  N ecav ; y2ecav  y3ecav  0;
If D ecav = 0 then y1ecav  M ecav  N ecav ; y2ecav  y3ecav  ( M ecav  N ecav ) / 2;
If D ecav < 0 and B ecav > 0 then





 ecav  arccos  

ecav
1

y

( B ecav )2 / 4 

(  Aecav )3 / 27 

(A.75)

Aecav
Aecav
Aecav
ecav
ecav
ecav
ecav
2 
cos( ); y2  2 
cos(  2 / 3); y3  2 
cos( ecav  4 / 3)
3
3
3
(A.76)

If D ecav < 0 and B ecav ≤ 0 then
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 ( B ecav )2 / 4 

 (  Aecav )3 / 27 



 ecav  arccos 

y1ecav  2 

(A.77)

Aecav
Aecav
Aecav
cos( ecav ); y2ecav  2 
cos( ecav  2 / 3); y3ecav  2 
cos( ecav  4 / 3)
3
3
3
(A.78)

ziecav  yiecav 

p ecav
, i  1, 2, 3.
3

(A.79)

[Gs ]ecav
 max{z1ecav , z2ecav , z3ecav }
f

[ R 1 ]ecav
np , f 

ecav
 2 np , f

[R ]



[ R 1 ]ecav
np ,tot


[ L]
[ L]
1
 [Gs ]ecav

1 

f
 K  1,C K  1,H K  1,C
 K  1,L



[ L]
[ L]
1
 [Gs ]ecav

1 

f
 K  2, L
 K  2,C K  2, H K  2,C

ecav
s np

[ R 1G ]

ecav
s np

[ LR 2 ]ecav
np


 
 

(A.81)


 
 

(A.82)

[ R 2 ]ecav
np ,tot

[ LR 1 ]ecav
np

[ LR 1G ]

(A.80)

[ L] [ R 1 ]ecav
np , f
K

(A.83)

1, L

ecav
[ R 1 ]ecav
np , f [Gs ] f

K

ecav
[ L] [ R 1 ]ecav
np , f [Gs ] f

K

1,C

[ L] [ R 2 ]ecav
np , f
K

2, L

(A.84)

1,C

K

(A.85)

1, H

(A.86)
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ecav
[ R 2 ]ecav
np , f [Gs ] f

ecav
s np

[ R 2G ]

K

ecav
s np

[ LR 2G ]

d [ R 1 ]ecav
PKA,tot
dt
ecav
d [ R 1 ]GRK
2,tot
dt

d [ R 2 ]ecav
PKA,tot
dt
ecav
d [ R 2 ]GRK
2,tot

dt
d [Gs ]ecav
,GTP
dt

(A.87)

2,C

ecav
[ L] [ R 2 ]ecav
np , f [Gs ] f

K

K

2,C

(A.88)

2, H

kPKA [C ]ecav [ R 1 ]ecav
np ,tot

kGRK 2

ecav
[ LR 1 ]np

ecav
[ LR 1Gs ]np

kPKA [C ]ecav [ R 2 ]ecav
np ,tot

kGRK 2

[ LR 2 ]ecav
np

kact 2,Gs 1[ R 1Gs ]ecav
np

kPKA [ R 1 ]ecav
PKA,tot

ecav
kGRK 2 [ R 1 ]GRK
2,tot

kPKA [ R 2 ]ecav
PKA,tot

[ LR 2Gs ]ecav
np

ecav
kGRK 2 [ R 2 ]GRK
2,tot

kact 2,Gs 2 [ R 2Gs ]ecav
np

kact1,Gs 1[ LR 1Gs ]ecav
np

dt
d [Gi ]ecav
,GTP
dt
d [Gi ]ecav
,GDP
dt

d [G ]ecav
dt

(A.90)

(A.91)

(A.92)

ecav
kact1,Gs 2 [ LR 2Gs ]np

(A.93)

khyd ,Gs [Gs ]ecav
,GTP

d [Gs ]ecav
,GDP

(A.89)

khyd ,Gs [Gs ]ecav
,GTP

kreas ,Gs [G]ecav [Gs ]ecav
,GDP

(A.94)

kact 2,Gi [ R 2Gi ]ecav
PKA

kact1,Gi [ LR 2Gi ]ecav
PKA

(A.95)

khyd ,Gi [Gi ]ecav
,GTP

kact 2,Gs 1[ R 1Gs ]ecav
np
kact 2,Gi [ R 2Gi ]ecav
PKA

khyd ,Gi [Gi ]ecav
,GTP

kreas ,Gi [G]ecav [Gi ]ecav
,GDP

kact 2,Gs 2 [ R 2Gs ]ecav
np
kact1,Gi [ LR 2Gi ]ecav
PKA

kreas ,Gi [G ]ecav [Gi ]ecav
,GDP

kact1,Gs 1[ LR 1Gs ]ecav
np
kreas ,Gs [G ]ecav [Gs ]ecav
,GDP

(A.96)

ecav
kact1,Gs 2 [ LR 2Gs ]np

(A.97)
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Cytosol
cyt
[ R 1 ]tot

f cyt1 [ R 1 ]tot

[Gs ]cyt

fGscyt [Gs ]tot

[ R 1 ]cyt
np ,tot

cyt
[ R 1 ]tot

1

a cyt1

K

bcyt1

K

(A.98)

Vcell
Vcyt

[Gs ]cyt,GTP

[ R 1 ]cyt
PKA,tot

[ L]

K

1, H

[Gs ]cyt,GDP

K

cyt
[ R 1 ]GRK
2,tot

(A.100)

[ L]

(A.101)

bcyt1

[ R 1 ]cyt
np , f

[ R 1 ]cyt
K
np ,tot

[ L]

1, H

[ R 1 ]cyt
np ,tot K

K

1,C

4 a cyt1 c cyt1

2 a cyt1

[Gs ]cyt

[G ]

cyt
1 np , f

1 [R ]

cyt
1 np

[ LR ]

[ R 1Gs ]cyt
np

cyt
s np

1
K

1,C

[ L]
K 1,C K

[ L] [ R 1 ]cyt
np , f
K

1, H

[ L]

K

1,C

K

1, H

1

[ L]
K 1, L

(A.102)

(A.103)

1, H

(bcyt1 )2

cyt
s f

[ LR 1G ]

(A.99)

1, L

[Gs ]cyt

ccyt1

1, L

Vcell
Vcyt

(A.104)

(A.105)
1, H

(A.106)

1, L

cyt
[ R 1 ]cyt
np , f [Gs ] f

K

cyt
[ L] [ R 1 ]cyt
np , f [Gs ] f

K

(A.107)

1,C

1,C

K

1, H

(A.108)
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d [ R 1 ]cyt
PKA,tot
dt
cyt
d [ R 1 ]GRK
2,tot
dt

kact 2,Gs

dt

kact 2,Gs

dt

cyt
[ LR 1 ]np

kGRK 2

kPKA [ R 1 ]cyt
PKA,tot

cyt
[ LR 1Gs ]np

(A.109)

cyt
kGRK 2 [ R 1 ]GRK
2,tot

(A.110) (
A.110)

d [Gs ]cyt,GTP

d [G]cyt

kPKA [C ]cyt [ R 1 ]cyt
np ,tot

d [Gs ]cyt,GDP
dt

1

1

[ R 1Gs ]cyt
np

[ R 1Gs ]cyt
np

khyd ,Gs [Gs ]cyt,GTP

kact1,Gs

kact1,Gs

1

1

[ LR 1Gs ]cyt
np

[ LR 1Gs ]cyt
np

khyd ,Gs [Gs ]cyt,GTP

(A.111)

kreas ,Gs [G]cyt [Gs ]cyt,GDP

(A.112)

kreas,Gs [G]cyt [Gs ]cyt,GDP

(A.113)

Adenylyl cyclase module

Parameter

Definition

Value

Reference

Km,ATP

Adenylyl cyclase affinity for ATP

340 μM

Bondarenko (27)

[ATP]

ATP concentration

5000 μM

Heijman et al. (26)

[AC]tot

Total cellular AC concentration

0.02622 μM

Post et al. (19)

f AC 56, AC 47

Fraction of AC that is of type 5 or

0.74

Heijman et al. (26)

0.0875

Heijman et al. (26)

0.1648

Heijman et al. (26)

0.0852 μM

Heijman et al. (26)

6
cav
f AC
56

Fraction of AC5/6 located in
caveolar

ecav
f AC
47

Fraction of AC4/7 located in
extracaveolar

K mAC,Gs56

AC5/6 affinity for Gsα

137
hAC 56,Gs

Hill coefficient for AC5/6

1.357

Heijman et al. (26)

1.430

Gao et al. (103)

0.003793 μM

Gao et al. (103)

1.0842

Gao et al. (103)

activation by Gsα

VGAC 56

Maximum amplification of AC5/6
by Gβγ

K mAC,G56

Affinity constant for Gβγ
modulation of AC5/6

hAC 56,G

Hill coefficient for Gβγ
modulation of AC5/6

AC56basal

Basal AC5/6 activity

0.0377

Heijman et al. (26)

AF56

Amplification factor for AC5/6

51.1335 s1

Bondarenko (27)

K mAC,Gs47

AC4/7 affinity for Gsα

0.05008 μM

Zimmermann and Taussig
(104)

hAC 47,Gs

Hill coefficient for AC4/7

1.1657

activation by Gsα

VGAC 47

Maximum amplification of AC4/7

(104)
1.3500

by Gβγ

K mAC,G47

Affinity constant for Gβγ

Hill coefficient for Gβγ

Zimmermann and Taussig
(104)

0.004466 μM

modulation of AC4/7

hAC 47,G

Zimmermann and Taussig

Zimmermann and Taussig
(104)

0.8700

modulation of AC4/7

Zimmermann and Taussig
(104)

AC47basal

Basal AC4/7 activity

0.04725

Bondarenko (27)

AF47

Amplification factor for AC4/7

9.283 s1

Bondarenko (27)

Gs-dependence of inactivation by

0.482 μM

Heijman et al. (26)

0.662

Heijman et al. (26)

56
K mAC,GsGi

Gi for AC56

hAC 56,GsGi

Hill coefficient for Gs/Gi
interaction of AC56

138
Maximum reduction in Gi

AC 56
VGsGi

0.857

Heijman et al. (26)

0.0465 μM

Heijman et al. (26)

inhibition by Gs
AC56 affinity for inhibition by Gi

K mAC,Gi56

Caveolar

[ AC 56]cav

k

cav
AC 56

cav
f AC
56 f AC 56, AC 47 [ AC ]tot

[Gs ]cav,GTP

AF56 AC 56basal

1

1

K

AC 56
m ,Gs

AC 56
VGsGi
[Gs ]cav,GTP
56
K mAC,GsGi

d [cAMP]cav
AC 56
dt

cav
k AC
56

Vcell
Vcav

(A.114)
hAC 56,Gs

hAC 56,Gs
cav
s ,GTP

[G ]

hAC 56,GsGi

[Gs ]cav,GTP

1

hAC 56,GsGi

VGAC 56 [Gs ]cav
K mAC,Gs56

hAC 56,Gs
hAC 56,Gs

[Gs ]cav

[Gi ]cav,GTP
K mAC,Gi56

(A.115)

[Gi ]cav,GTP

[ AC 56]cav [ ATP]
K m, ATP [ ATP]

(A.116)

Extracaveolar

[ AC 47]ecav

k

ecav
AC 47

ecav
f AC
f AC 56, AC 47 ) [ AC ]tot
47 (1

AF47 AC 47basal

d [cAMP]ecav
AC 47
dt

Cytosol

ecav
k AC
47

[Gs ]ecav
,GTP
K mAC,Gs47

Vcell
Vecav
hAC 47,Gs

[Gs ]ecav
,GTP

[ AC 47]ecav [ ATP]
K m, ATP [ ATP]

(A.117)

hAC 47,Gs

1

VGAC 47 [Gs ]ecav
K mAC,Gs47

hAC 47,Gs

[Gs ]ecav

hAC 47,Gs

(A.118)

(A.119)
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Vcell
Vcyt

[ AC56]cyt

cav
(1 f AC
56 ) f AC 56, AC 47 [ AC ]tot

[ AC 47]cyt

ecav
(1 f AC
f AC 56, AC 47 ) [ AC ]tot
47 ) (1

cyt
k AC
56

AF56 AC 56basal

d [cAMP]cyt
AC 56
dt

cyt
k AC
47

cyt
k AC
56

cyt
k AC
47

K mAC,Gs56

Vcell
Vcyt

(A.121)

hAC 56,Gs

[Gs ]cyt,GTP

hAC 56,Gs

1

VGAC 56 [Gs ]cyt
K mAC,Gs56

hAC 56,Gs
hAC 56,Gs

[Gs ]cyt

[ AC 56]cyt [ ATP]
K m, ATP [ ATP]

AF47 AC 47basal

d [cAMP]cyt
AC 47
dt

[Gs ]cyt,GTP

(A.120)

[Gs ]cyt,GTP
K mAC,Gs47

(A.123)

hAC 47,Gs

[Gs ]cyt,GTP

[ AC 47]cyt [ ATP]
K m, ATP [ ATP]

(A.122)

hAC 47,Gs

1

VGAC 47 [Gs ]cyt
K mAC,Gs47

hAC 47,Gs

[Gs ]cyt

hAC 47,Gs

(A.124)

(A.125)

